{"doc_id": "acco_parpi__v00000000", "chunk_id": "000000", "text": "# acco_parpi", "section": "acco_parpi", "page_from": null, "page_to": null, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "bf5d3169e2e367f41e3634407842c269aae51eeb33a448999734e17f54e61d54"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000001", "text": "rapid communications\nPARP Inhibitors in the Management of Ovarian\nCancer: ASCO Guideline\nWilliam P. Tew, MD1; Christina Lacchetti, MHSc2; Annie Ellis3,4; Kathleen Maxian, BSW5; Susana Banerjee, PhD6; Michael Bookman, MD7;\nMonica Brown Jones, MD8; Jung-Min Lee, MD9; St´ephanie Lheureux, MD, PhD10; Joyce F. Liu, MD11; Kathleen N. Moore, MD12;\nCarolyn Muller, MD13; Patricia Rodriguez, MD14; Christine Walsh, MD15; Shannon N. Westin, MD16; and Elise C. Kohn, MD9\nabstract\nPURPOSE To provide recommendations on the use of poly(ADP-ribose) polymerase inhibitors (PARPis) for\nmanagement of epithelial ovarian, tubal, or primary peritoneal cancer (EOC).\nMETHODS Randomized, controlled, and open-labeled trials published from 2011 through 2020 were identiﬁed in\na literature search. Guideline recommendations were based on the review of the evidence, US Food and Drug\nAdministration approvals, and consensus when evidence was lacking.\nRESULTS The systematic review identiﬁed 17 eligible trials.\nRECOMMENDATIONS The guideline pertains to patients who are PARPi na¨ıve. All patients with newly diagnosed,", "section": "PARP Inhibitors in the Management of Ovarian", "page_from": 1, "page_to": 1, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "b2999cfbdbd0d3dd22a5d1a92e822e70ba32c6b81cf585bc1573f958f2f21af4"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000002", "text": "RESULTS The systematic review identiﬁed 17 eligible trials.\nRECOMMENDATIONS The guideline pertains to patients who are PARPi na¨ıve. All patients with newly diagnosed,\nstage III-IV EOC whose disease is in complete or partial response to ﬁrst-line, platinum-based chemotherapy with\nhigh-grade serous or endometrioid EOC should be offered PARPi maintenance therapy with niraparib. For\npatients with germline or somatic pathogenic or likely pathogenic variants in BRCA1 (g/sBRCA1) or BRCA2\n(g/sBRCA2) genes should be treated with olaparib. The addition of olaparib to bevacizumab may be offered to\npatients with stage III-IV EOC with g/sBRCA1/2 and/or genomic instability and a partial or complete response\nto chemotherapy plus bevacizumab combination. Maintenance therapy (second line or more) with single-\nagent PARPi may be offered for patients with EOC who have not received a PARPi and have responded to\nplatinum-based therapy regardless of BRCA mutation status. Treatment with a PARPi should be offered to\npatients with recurrent EOC that has not recurred within 6 months of platinum-based therapy, who have not", "section": "PARP Inhibitors in the Management of Ovarian", "page_from": 1, "page_to": 1, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "6218b2f7a0562ab972c53f4803b08b270e2f77aaf2f9ebe8ab68b9e57c4046d8"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000003", "text": "patients with recurrent EOC that has not recurred within 6 months of platinum-based therapy, who have not\nreceived a PARPi and have a g/sBRCA1/2, or whose tumor demonstrates genomic instability. PARPis are not\nrecommended for use in combination with chemotherapy, other targeted agents, or immune-oncology agents\nin the recurrent setting outside the context of a clinical trial. Recommendations for managing speciﬁc adverse\nevents are presented. Data to support reuse of PARPis in any setting are needed.\nAdditional information is available at www.asco.org/gynecologic-cancer-guidelines.\nJ Clin Oncol 38:3468-3493. © 2020 by American Society of Clinical Oncology\nINTRODUCTION\nIn 2020, it is estimated that there will be 21,750 new\ncases of ovarian cancers diagnosed in the United\nStates, and despite advances in treatment, an esti-\nmated 13,940 women will die of the disease.1 A\nwoman’s risk of getting ovarian cancer during her\nlifetime is approximately 1 in 78 and her lifetime\nchance of dying of ovarian cancer is about 1 in 108.1\nApproximately 85%-90% of all ovarian cancers are\nepithelial in origin, and approximately 70% of all ep-\nithelial ovarian cancers are high-grade serous (HGS)", "section": "PARP Inhibitors in the Management of Ovarian", "page_from": 1, "page_to": 1, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "91469657af19456c2e5157c0f1da40bf4da120e5110cc9a9074ec8146f047556"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000004", "text": "Approximately 85%-90% of all ovarian cancers are\nepithelial in origin, and approximately 70% of all ep-\nithelial ovarian cancers are high-grade serous (HGS)\nadenocarcinoma.2 Despite initial therapy, usually\nconsisting of surgical cytoreduction and platinum-\ntaxane combination therapy, the majority of women\nwith advanced-stage epithelial ovarian, tubal, or pri-\nmary peritoneal cancer (hereinafter referred to as\nEOC), will have a relapse of their disease and require\nadditional treatment.3\nGermline alterations in breast cancer 1 (gBRCA1) and\nbreast cancer 2 (gBRCA2) genes have been identiﬁed\nin up to 17% of women diagnosed with EOC, and\nsomatic mutations are found in an additional 7%.4-7\nApproximately 41%-50% of EOCs are estimated to\nexhibit homologous recombination deﬁciency (HRD)\ninvolved in repair of DNA damage and replication.8\nThe introduction of poly(ADP-ribose) polymerase\nASSOCIATED\nCONTENT\nAppendix\nData Supplement\nAuthor afﬁliations\nand support\ninformation (if\napplicable) appear\nat the end of this\narticle.\nAccepted on June 25,\n2020 and published at\nascopubs.org/journal/\njco on August 13,\n2020: DOI https://doi.\norg/10.1200/JCO.20.\n01924\nClinical Practice\nGuidelines Committee", "section": "PARP Inhibitors in the Management of Ovarian", "page_from": 1, "page_to": 1, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "57260ba16c56cfee35eafa9dd26a60460043824069cb1c80b63fcfcfe65384d3"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000005", "text": "at the end of this\narticle.\nAccepted on June 25,\n2020 and published at\nascopubs.org/journal/\njco on August 13,\n2020: DOI https://doi.\norg/10.1200/JCO.20.\n01924\nClinical Practice\nGuidelines Committee\napproval: June 15,\n2020\nReprint Requests:\n2318 Mill Rd, Suite\n800, Alexandria, VA\n22314; guidelines@\nasco.org\n3468 Volume 38, Issue 30\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158\nCopyright © 2025 American Society of Clinical Oncology. All rights reserved.", "section": "PARP Inhibitors in the Management of Ovarian", "page_from": 1, "page_to": 1, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "f1c01949327252937a254e6d9e3d138b63b9d3e122eef43559418e611fc525b6"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000006", "text": "THE BOTTOM LINE\nPARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline\nGuideline Questions\n1. Should PARPi therapy for EOC be repeated over the course of treatment?\n2. In which patients with newly diagnosed EOC are PARPis recommended?\na. What are the histologic types of EOC for which PARPis are recommended?\nb. What are the biomarker subsets for which PARPis are recommended?\n3. Is PARPi monotherapy recommended for recurrent EOC? If so,\na. In which settings (eg, second-line maintenance or treatment of recurrent disease)?\nb. At what dose and duration?\n4. Are there settings where PARPis in combination with chemotherapy or other targeted therapy are recommended?\n5. How should clinicians manage the speciﬁc toxicities of the various PARPis?\nTarget Population\nPatients diagnosed with epithelial ovarian, tubal, or primary peritoneal cancer (EOC) who have not previously received\na poly(ADP-ribose) polymerase inhibitor (PARPi).\nTarget Audience\nMedical, radiation, and surgical oncologists; gynecologic oncologists; gynecologists; advanced practice and other health\nprofessionals; women with ovarian cancer and their families.\nMETHODS", "section": "THE BOTTOM LINE", "page_from": 2, "page_to": 2, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "bbde313e60531b9716dba8fbc00b8999f44749064f92fa92faf598a1dc38e289"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000007", "text": "Medical, radiation, and surgical oncologists; gynecologic oncologists; gynecologists; advanced practice and other health\nprofessionals; women with ovarian cancer and their families.\nMETHODS\nAn Expert Panel was convened to develop clinical practice guideline recommendations on the basis of a systematic review of\nthe medical literature and Food and Drug Administration (FDA) regulatory approvals.\nRecommendations\nNote: These recommendations pertain only to patients with EOC who have not previously received a PARPi. The recommendations\nare based on clinical trial results and FDA approvals and do not necessarily capture regulatory approvals in other jurisdictions.\nRepeating PARPi\nRecommendation 1.0.\nRepeating PARPi therapy in the treatment of EOC is not recommended at this time. Consideration\nshould be made as to the best time in the life cycle of an individual patient’s EOC in which to use PARPi; clinical trial\nparticipation is encouraged (Type: informal consensus, beneﬁts outweigh harms; Evidence quality: insufﬁcient; Strength of\nrecommendation: strong).\nNewly Diagnosed Ovarian Cancer", "section": "THE BOTTOM LINE", "page_from": 2, "page_to": 2, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "3fea3a7af57612815e67ef3c7d6aeaecd8f28f47d2e378f881db45f7d180deef"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000008", "text": "participation is encouraged (Type: informal consensus, beneﬁts outweigh harms; Evidence quality: insufﬁcient; Strength of\nrecommendation: strong).\nNewly Diagnosed Ovarian Cancer\nRecommendation 2.0. PARPis are not recommended for use in initial treatment of early stage (stage I-II) EOC because there is\ninsufﬁcient evidence to support use in this population (Type: informal consensus, beneﬁts outweigh harms; Evidence quality:\ninsufﬁcient; Strength of recommendation: strong).\nRecommendation 2.1.\nWomen with newly diagnosed stage III-IV EOC that is in complete or partial response to ﬁrst-line\nplatinum-based chemotherapy should be offered PARPi maintenance therapy with olaparib (for those with germline or\nsomatic pathogenic or likely pathogenic variants in BRCA1 or BRCA2 genes) or niraparib (all women) in high-grade serous\n(HGS) or endometrioid ovarian cancer.\n• PARPi maintenance therapy should consist of olaparib (300 mg orally every 12 hours for 2 years) or niraparib (200-\n300 mg orally daily for 3 years). Longer duration could be considered in selected individuals. (Type: evidence based,\nbeneﬁts outweigh harms; Evidence quality: high; Strength of recommendation: strong).", "section": "THE BOTTOM LINE", "page_from": 2, "page_to": 2, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "7f3d30a01347799fc69e9770077cff077f041779e533da3ebbffe5213eaf687d"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000009", "text": "beneﬁts outweigh harms; Evidence quality: high; Strength of recommendation: strong).\nRecommendation 2.2. The addition of olaparib to bevacizumab maintenance may be offered to patients who have stage III-IV\nHGS or endometrioid ovarian cancer and germline or somatic pathogenic or likely pathogenic variants in BRCA1 or BRCA2\ngenes and/or genomic instability, as determined by Myriad myChoice CDx, and who have had a partial or complete response to\nchemotherapy plus bevacizumab combination (Type: evidence based, beneﬁts outweigh harms; Evidence quality: strong;\nStrength of recommendation: strong).\nRecommendation 2.3.\nInclusion of the PARPi veliparib with combination chemotherapy followed by veliparib maintenance\ntherapy cannot be recommended at this time. There are no data that this approach is superior, equal, or less toxic than\na switch maintenance (Type: evidence based; beneﬁt/harms ratio unknown; Evidence quality: intermediate; Strength of\nrecommendation: strong).\n(continued on following page)\nJournal of Clinical Oncology\n3469\nPARP Inhibitors in Ovarian Cancer\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158", "section": "THE BOTTOM LINE", "page_from": 2, "page_to": 2, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "929557b277f3c508bc9018a76b0f6784ee8c80ad43ffc4816d4d01735db84079"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000010", "text": "(continued on following page)\nJournal of Clinical Oncology\n3469\nPARP Inhibitors in Ovarian Cancer\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158\nCopyright © 2025 American Society of Clinical Oncology. All rights reserved.", "section": "THE BOTTOM LINE", "page_from": 2, "page_to": 2, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "23f19e4db507c1989df33b98120e59220ebc6f71b0b1ed8fdf41073db25c7774"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000011", "text": "THE BOTTOM LINE (CONTINUED)\nNote: As of this writing, veliparib is not commercially available.\nRecurrent Ovarian Cancer: Second-Line or Greater Maintenance and Treatment\nRecommendation 3.0. PARPi monotherapy maintenance (second-line or more) may be offered to patients with EOC who have\nnot already received a PARPi and who have responded to platinum-based therapy regardless of BRCA mutation status;\ntreatment is continued until progression of disease or toxicity despite dose reductions and best supportive care.\n• Options include: olaparib 300 mg every 12 hours; rucaparib 600 mg every 12 hours; niraparib 200-300 mg once daily.\n(Type: evidence based, beneﬁts outweigh harms; Evidence quality: high; Strength of recommendation: strong).\nRecommendation 3.1. Treatment with a PARPi should be offered to patients with recurrent EOC who have not already received\na PARPi and have a germline or somatic pathogenic or likely pathogenic variants in BRCA1 or BRCA2 genes.\n• Options include: olaparib 300 mg every 12 hours; rucaparib 600 mg every 12 hours; niraparib 200-300 mg once daily\n(Type: evidence based, beneﬁts outweigh harms; Evidence quality: high; Strength of recommendation: strong).", "section": "THE BOTTOM LINE (CONTINUED)", "page_from": 3, "page_to": 3, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "0827415e7a7e785bf106cecf5d3fa4e07559312921fa4900e889ac085de19485"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000012", "text": "(Type: evidence based, beneﬁts outweigh harms; Evidence quality: high; Strength of recommendation: strong).\nRecommendation 3.2. Treatment with a PARPi monotherapy should be offered to patients with recurrent EOC who have not\nalready received a PARPi and whose tumor demonstrates genomic instability, as determined by Myriad myChoice CDx, and\nhas not recurred within 6 months of platinum-based therapy (Type: evidence based, beneﬁts outweigh harms; Evidence\nquality: high; Strength of recommendation: strong).\nRecommendation 3.3.\nPARPis are not recommended for treatment of BRCA wild-type or platinum-resistant recurrent EOC\n(Type: evidence based, beneﬁts outweigh harms; Evidence quality: high; Strength of recommendation: strong).\nPARPis in Combination\nRecommendation 4.0.\nPARPi are not recommended for use in combination with chemotherapy, other targeted agents, or\nimmune-oncology agents in the recurrent setting outside the context of a clinical trial. Clinical trial participation is encouraged\n(Type: informal consensus, beneﬁts outweigh harms; Evidence quality: insufﬁcient; Strength of recommendation: strong).\nManagement of Adverse Events\nRecommendation 5.0 Anemia:", "section": "THE BOTTOM LINE (CONTINUED)", "page_from": 3, "page_to": 3, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "a484db34a7b39bce3a52efecff32d00c883358b8fbd329e390e993d9638eedc4"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000013", "text": "(Type: informal consensus, beneﬁts outweigh harms; Evidence quality: insufﬁcient; Strength of recommendation: strong).\nManagement of Adverse Events\nRecommendation 5.0 Anemia:\na. Patients requiring a blood transfusion for symptom relief and/or hemoglobin level , 8 g/dL should be monitored. PARPi\ndose should be reduced with evidence of repeated anemia to avoid multiple transfusions.\nb. Patients with progressive anemia may be offered growth factor per ASCO guidelines and physician and patient comfort.\n(Type: informal consensus, beneﬁts outweigh harms; Evidence quality: insufﬁcient; Strength of recommendation: moderate).\nRecommendation 5.1 Neutropenia:\na. Growth factor is not indicated for use in patients receiving daily PARPi.\nb. Neutropenia (grade 4 lasting at least 5-7 days or associated with fever) should result in dose hold until recovery of\ninfection and granulocyte count, followed by dose reduction. Growth factor support may be used in this setting to\nsupport patient safety during the drug hold.\n(Type: informal consensus, beneﬁts outweigh harms; Evidence quality: insufﬁcient; Strength of recommendation: moderate).\nRecommendation 5.2 Platelets:", "section": "THE BOTTOM LINE (CONTINUED)", "page_from": 3, "page_to": 3, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "5582e7adc49121277f735168ff1abac994f47f264ce43bba5f3d8a20096cc9b7"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000014", "text": "support patient safety during the drug hold.\n(Type: informal consensus, beneﬁts outweigh harms; Evidence quality: insufﬁcient; Strength of recommendation: moderate).\nRecommendation 5.2 Platelets:\na. Thrombocytopenia is most common with niraparib. Niraparib dosing guidelines should be used to lower starting dose\n(200 mg) based on weight and platelet count.\nb. Discontinue PARPi for persistent thrombocytopenia or signiﬁcant bleeding despite dose reduction.\n(Type: informal consensus, beneﬁts outweigh harms; Evidence quality: insufﬁcient; Strength of recommendation: moderate)\nRecommendation 5.3 Persistent cytopenia:\na. Evaluation for treatment-related myelodysplastic syndrome/acute myeloid leukemia should be initiated in patients with\npersistent cytopenia that occurs despite drug hold.\n(Type: informal consensus, beneﬁts outweigh harms; Evidence quality: insufﬁcient; Strength of recommendation: moderate).\nRecommendation 5.4 Nausea:\na. Many patients will have tachyphylaxis of nausea symptoms over the ﬁrst cycle of therapy.\nb. Persistent nausea requiring daily antiemetic intervention, causing a reduction in performance status, and/or resulting in", "section": "THE BOTTOM LINE (CONTINUED)", "page_from": 3, "page_to": 3, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "303f0791a002f938e626daf636dc17bd673ee7a14387546bbfde9e67e81ab067"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000015", "text": "b. Persistent nausea requiring daily antiemetic intervention, causing a reduction in performance status, and/or resulting in\n. 5% weight loss should result in dose reduction.\n(Type: informal consensus, beneﬁts outweigh harms; Evidence quality: insufﬁcient; Strength of recommendation: moderate).\n(continued on following page)\n3470 © 2020 by American Society of Clinical Oncology\nVolume 38, Issue 30\nTew et al\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158\nCopyright © 2025 American Society of Clinical Oncology. All rights reserved.", "section": "THE BOTTOM LINE (CONTINUED)", "page_from": 3, "page_to": 3, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "8b8db5490b7ef082c4dc09dff99d0720382451b8601649af4117d712fc281521"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000016", "text": "inhibitors (PARPis) has led to major change in the ap-\nproaches to EOC management across the treatment life\ncycle. In 2014, the US Food and Drug Administration\n(FDA) approved the ﬁrst PARPi, olaparib, as a treatment\nof gBRCA EOC for patients who had received $ 3 prior\nlines of chemotherapy. Rucaparib received FDA approval\nfor treatment of g/sBRCA recurrent disease in 2016.\nApproval for niraparib and, subsequently, olaparib as\nmaintenance therapy for women with complete or partial\nresponse to platinum-based chemotherapy was granted\nin 2017. Since then, the FDA has expanded the regulatory\napproval of PARPis, thereby allowing more patients to\nbeneﬁt from these agents and access the drugs earlier in\ntreatment. Recent studies have conﬁrmed that the efﬁ-\ncacy of PARPis is enhanced not only in g/sBRCA EOC but\nalso in cancers in which HRD is caused by other un-\nderlying etiologies. The applications of PARPis in the\nmanagement of EOC are complex and all approvals to\ndate are predicated on the absence of prior exposure to\nPARPis.\nThe purpose of this guideline is to provide clinicians,\nother health care practitioners, patients, and caregivers", "section": "THE BOTTOM LINE (CONTINUED)", "page_from": 4, "page_to": 4, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "ed03f598c6aa191a815684d53583f4ee9606386b78bf064a0f9c29f5e8e25b9f"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000017", "text": "date are predicated on the absence of prior exposure to\nPARPis.\nThe purpose of this guideline is to provide clinicians,\nother health care practitioners, patients, and caregivers\nwith recommendations regarding the role of PARPis in\nthe management of EOC based on the best available\nevidence.\nGUIDELINE QUESTIONS\nThis clinical practice guideline addresses ﬁve overarching\nclinical questions:\n1. Should PARPi therapy for EOC be repeated over the\ncourse of treatment?\n2. In which patients with newly diagnosed EOC are\nPARPis recommended?\n2a. What are the histologic types of EOC for which\nPARPis are recommended?\n2b. What are the biomarker subsets for which PARPis\nare recommended?\n3. Is PARPi monotherapy recommended for recurrent\nEOC? If so:\n3a. In which settings (eg, second-line maintenance or\ntreatment of recurrent disease)?\n3b. At what dose and duration?\n4. Are there settings where PARPis in combination\nwith chemotherapy or other targeted therapy are\nrecommended?\n5. How should clinicians manage the speciﬁc toxicities of\nthe various PARPis?\nMETHODS\nGuideline Development Process\nThis systematic review-based guideline was developed by", "section": "THE BOTTOM LINE (CONTINUED)", "page_from": 4, "page_to": 4, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "36c58a4867b7fa7699b986948bad8c2098c2af83bc51b19830d3edcbb826eddd"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000018", "text": "recommended?\n5. How should clinicians manage the speciﬁc toxicities of\nthe various PARPis?\nMETHODS\nGuideline Development Process\nThis systematic review-based guideline was developed by\na multidisciplinary Expert Panel, which included two patient\nrepresentatives and an ASCO guidelines staff member with\nhealth research methodology expertise (Appendix Table\nA1, online only). The Expert Panel met in person, via\nteleconference, and/or webinar, and corresponded through\ne-mail. Based on the consideration of the evidence and\nFDA regulatory approval, the authors were asked to con-\ntribute to the development of the guideline, provide critical\nreview, and ﬁnalize the guideline recommendations. The\nguideline recommendations were sent for an open com-\nment period of 2 weeks, allowing the public to review and\ncomment on the recommendations after submitting\na conﬁdentiality agreement. These comments were taken\ninto consideration while ﬁnalizing the recommendations.\nMembers of the Expert Panel were responsible for reviewing\nand approving the penultimate version of the guideline,\nwhich was then circulated for external review, and sub-\nmitted to Journal of Clinical Oncology (JCO) for editorial", "section": "THE BOTTOM LINE (CONTINUED)", "page_from": 4, "page_to": 4, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "e1feac97f605182f281964197b600ec9014f6a4ac859321550726705c991ec3d"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000019", "text": "and approving the penultimate version of the guideline,\nwhich was then circulated for external review, and sub-\nmitted to Journal of Clinical Oncology (JCO) for editorial\nreview and consideration for publication. All ASCO guide-\nlines are ultimately reviewed and approved by the Expert\nPanel and the ASCO Clinical Practice Guidelines Com-\nmittee before publication. All funding for the administration\nof the project was provided by ASCO.\nThe recommendations were developed by using a sys-\ntematic review of the literature conducted in PubMed for\nrandomized controlled trials (RCTs) published from Jan-\nuary 1, 2009, to May 3, 2019. The search was then\nupdated on April 20, 2020, and relevant trials released at\nESMO (European Society for Medical Oncology) 2019 and\nASCO 2020 were also identiﬁed. The FDA’s Center for Drug\nEvaluation and Research database was also searched for\nregulatory information. Articles were selected for inclusion\nin the systematic review of the evidence on the basis of the\nfollowing criteria:\nTHE BOTTOM LINE (CONTINUED)\nASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care, and that all patients", "section": "THE BOTTOM LINE (CONTINUED)", "page_from": 4, "page_to": 4, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "641f0221b4b5ea528facce306308c14e7e34a3dfea47eba794dd154682921058"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000020", "text": "following criteria:\nTHE BOTTOM LINE (CONTINUED)\nASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care, and that all patients\nshould have the opportunity to participate.\nAdditional Resources\nMore information, including a supplement with additional evidence tables, slide sets, and clinical tools and resources, as well\nas a companion guideline on Germline and Somatic Tumor Testing in EOC,9 is available at www.asco.org/gynecologic-cancer-\nguidelines. The ASCO Guidelines Methodology Manual (available at www.asco.org/guideline-methodology) provides addi-\ntional information about the methods used to develop this guideline. Patient information is available at www.cancer.net.\nJournal of Clinical Oncology\n3471\nPARP Inhibitors in Ovarian Cancer\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158\nCopyright © 2025 American Society of Clinical Oncology. All rights reserved.", "section": "THE BOTTOM LINE (CONTINUED)", "page_from": 4, "page_to": 4, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "022673e11d5cddd5f60e9cfb10e94f1392c860d3748e589ff1af29af0959c14b"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000021", "text": "• Population: Adult women with EOC\n• Intervention: PARPi, including olaparib, niraparib,\nrucaparib, and veliparib\n• Comparator: Standard-of-care options or placebo\n• Outcomes: Therapeutic efﬁcacy (eg, survival, re-\nsponse rate), health-related quality of life, adverse\nevents\n• Fully published or recent meeting presentations of\nEnglish-language reports of phase II-III RCTs\n• For special circumstances, prospective, single-arm\ntrials were accepted.\nArticles were excluded from the systematic review if they\nwere (1) editorials, commentaries, letters, news articles,\ncase reports, narrative reviews; or (2) published in a non-\nEnglish language. The guideline recommendations were\ncrafted, in part, using the Guidelines Into Decision Support\n(GLIDES) methodology and accompanying BRIDGE-Wiz\nsoftware.9 In addition, a guideline implementability re-\nview was conducted. Based on the implementability review,\nrevisions were made to the draft to clarify recommended\nactions for clinical practice. Ratings for the type and\nstrength of recommendation, evidence, and potential bias\nare provided with each recommendation.\nThe ASCO Expert Panel and guidelines staff will work with", "section": "THE BOTTOM LINE (CONTINUED)", "page_from": 5, "page_to": 5, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "6c397063bb30933f6b1d21afdf3fac9998b6a6ba20d3fa59bd1bbb2b4f233e10"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000022", "text": "strength of recommendation, evidence, and potential bias\nare provided with each recommendation.\nThe ASCO Expert Panel and guidelines staff will work with\nco-chairs to keep abreast of any substantive updates to\nthe guideline. Based on formal review of the emerging\nliterature, ASCO will determine the need to update. The\nASCO Guidelines Methodology Manual (hereafter, Meth-\nodology Manual; available at www.asco.org/guidelines-\nmethodology) provides additional information about the\nguideline update process. This is the most recent in-\nformation as of the publication date.\nGuideline Disclaimer\nThe Clinical Practice Guidelines and other guidance\npublished herein are provided by the American Society of\nClinical Oncology, Inc. (ASCO) to assist providers in clinical\ndecision making. The information herein should not be\nrelied upon as being complete or accurate, nor should it be\nconsidered as inclusive of all proper treatments or methods\nof care or as a statement of the standard of care. With the\nrapid development of scientiﬁc knowledge, new evidence\nmay emerge between the time information is developed\nand when it is published or read. The information is not", "section": "THE BOTTOM LINE (CONTINUED)", "page_from": 5, "page_to": 5, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "1f095ab2a5547e739c0e74bd5f5b31034ab68f49802022229da5856d4d991c2f"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000023", "text": "rapid development of scientiﬁc knowledge, new evidence\nmay emerge between the time information is developed\nand when it is published or read. The information is not\ncontinually updated and may not reﬂect the most recent\nevidence. The information addresses only the topics spe-\nciﬁcally identiﬁed therein and is not applicable to other\ninterventions, diseases, or stages of diseases. This in-\nformation does not mandate any particular course of\nmedical care. Further, the information is not intended to\nsubstitute for the independent professional judgment of the\ntreating provider, as the information does not account for\nindividual variation among patients. Recommendations\nreﬂect high, moderate, or low conﬁdence that the\nrecommendation reﬂects the net effect of a given course of\naction. The use of words like “must,” “must not,” “should,”\nand “should not” indicates that a course of action is rec-\nommended or not recommended for either most or many\npatients, but there is latitude for the treating physician to\nselect other courses of action in individual cases. In all\ncases, the selected course of action should be considered\nby the treating provider in the context of treating the in-", "section": "THE BOTTOM LINE (CONTINUED)", "page_from": 5, "page_to": 5, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "9a7bad4cededdb5d2cde15442d0aa100db1351168a6494b999cff2fee4c78da3"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000024", "text": "select other courses of action in individual cases. In all\ncases, the selected course of action should be considered\nby the treating provider in the context of treating the in-\ndividual patient. Use of the information is voluntary. ASCO\nprovides this information on an “as is” basis and makes no\nwarranty, express or implied, regarding the information.\nASCO speciﬁcally disclaims any warranties of merchant-\nability or ﬁtness for a particular use or purpose. ASCO\nassumes no responsibility for any injury or damage to\npersons or property arising out of or related to any use of this\ninformation, or for any errors or omissions.\nGuideline and Conﬂicts of Interest\nThe Expert Panel was assembled in accordance with\nASCO’s Conﬂict of Interest Policy Implementation for\nClinical Practice Guidelines (“Policy,” found at www.asco.org/\nrwc). All members of the Expert Panel completed ASCO’s\ndisclosure form, which requires disclosure of ﬁnancial and\nother interests, including relationships with commercial\nentities that are reasonably likely to experience direct\nregulatory or commercial impact as a result of pro-\nmulgation of the guideline. Categories for disclosure in-", "section": "THE BOTTOM LINE (CONTINUED)", "page_from": 5, "page_to": 5, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "4e8129f379821e28ff7f6df4b9fb124d3e3b144515300b932820d35a7f45b726"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000025", "text": "entities that are reasonably likely to experience direct\nregulatory or commercial impact as a result of pro-\nmulgation of the guideline. Categories for disclosure in-\nclude employment; leadership; stock or other ownership;\nhonoraria, consulting or advisory role; speaker’s bureau;\nresearch funding; patents, royalties, other intellectual\nproperty; expert testimony; travel, accommodations, ex-\npenses; and other relationships. In accordance with the\nPolicy, the majority of the members of the Expert Panel did\nnot disclose any relationships constituting a conﬂict under\nthe Policy.\nRESULTS\nA total of 17 trials10-27 met eligibility criteria and form the\nevidentiary basis for the guideline recommendations\n(Table 1). Outcomes are summarized in Tables 2-5. The\nidentiﬁed trials were published between 2011 and 2020\nand compared, when comparators were part of the study\ndesign, PARPis to standard-of-care options or placebo. The\nprimary outcome for all trials was therapeutic efﬁcacy,\nexpressed as progression-free survival (PFS). Secondary\nand exploratory outcomes included overall survival (OS),\nobjective response rate, progression-free survival 2, time to", "section": "THE BOTTOM LINE (CONTINUED)", "page_from": 5, "page_to": 5, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "de8a54064ce92ab93492d7b072270cf5a805e1860908c23ce5fb6ead5bc454d8"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000026", "text": "expressed as progression-free survival (PFS). Secondary\nand exploratory outcomes included overall survival (OS),\nobjective response rate, progression-free survival 2, time to\ndiscontinuation of treatment or death, time to ﬁrst sub-\nsequent therapy or death (TFST), adverse events (AEs) and\nhealth-related quality of life (HRQoL). Characteristics of the\nstudies’ participants are outlined in Table 1. Figure 1\noutlines the current approval of PARPis in ovarian cancer.\nStudy Quality\nStudy design aspects related to individual study quality,\nstrength of evidence, strength of recommendations, and\nrisk of bias were assessed. Refer to the Methodology\n3472 © 2020 by American Society of Clinical Oncology\nVolume 38, Issue 30\nTew et al\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158\nCopyright © 2025 American Society of Clinical Oncology. All rights reserved.", "section": "THE BOTTOM LINE (CONTINUED)", "page_from": 5, "page_to": 5, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "6ae9671c44a662da2e379d3b3ec08d29996cf567696ff4ba3de14a3e0e937d19"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000027", "text": "Manual for more information and for deﬁnitions of ratings\nfor overall potential risk of bias.\nStudy quality was formally assessed for the fully published\ntrials identiﬁed but not for the study only available in ab-\nstract form.26 Design aspects related to the individual study\nquality were assessed by one reviewer, including factors\nsuch as blinding, allocation concealment, placebo control,\nintention to treat (ITT), funding sources, and so forth, and\ngenerally indicated a low to intermediate potential risk of\nbias for most of the identiﬁed evidence. In general, the\nquality of the included studies ranged from intermediate to\nhigh. Quality assessment ratings are found in the Data\nSupplement. Please refer to Methodology Manual for\ndeﬁnitions of ratings for overall potential risk of bias.\nKEY OUTCOMES OF INTEREST\nEfﬁcacy\nNewly diagnosed (frontline) maintenance setting. In the\nupfront setting, a total of four trials investigated PARPis for\nmaintenance therapy, two as monotherapy13,20 one as\ncombination therapy,24 and one as combination therapy\nfollowed by monotherapy.10\nThe SOLO1 trial20 investigated olaparib as ﬁrst-line main-\ntenance therapy in patients with gBRCA1/2 International", "section": "Study quality was formally assessed for the fully published", "page_from": 6, "page_to": 6, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "69d3a384a20ebd922b565e56198290573c90a83341bf1d9f7bb23967c8b05f70"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000028", "text": "combination therapy,24 and one as combination therapy\nfollowed by monotherapy.10\nThe SOLO1 trial20 investigated olaparib as ﬁrst-line main-\ntenance therapy in patients with gBRCA1/2 International\nFederation of Obstetrics and Gynecology (FIGO) stage III-\nIV, HGS or endometrioid EOC after a complete response\n(CR) or partial response (PR) to initial ﬁrst-line, platinum-\nbased chemotherapy. The trial showed that maintenance\nwith olaparib improved PFS compared with placebo\n(hazard ratio [HR], 0.30; 95% CI, 0.23 to 0.41). Although\nthe data from secondary outcomes are still immature, they\nsuggest olaparib delays TFST (median, 51.8 months)\ncompared with placebo (median, 15.1 months; TFST HR,\n0.30; 95% CI, 0.22 to 0.40).\nThe PRIMA trial13 investigated the efﬁcacy of niraparib\nmaintenance therapy after a response to platinum-based\nchemotherapy in patients with newly diagnosed, advanced\n(FIGO stage III-IV), HGS or endometrioid EOC at high risk\nfor relapse. The trial conﬁrmed that the clinical beneﬁt of\nﬁrst-line treatment with niraparib could be extended to all\npatients with advanced EOC regardless of HRD status,\nwhich was used as a stratiﬁcation factor. In the overall", "section": "Study quality was formally assessed for the fully published", "page_from": 6, "page_to": 6, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "bb1fa58f88f377380f21f60ff2eb9b4eb82bdda4a6bffa0eba4365569749371a"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000029", "text": "ﬁrst-line treatment with niraparib could be extended to all\npatients with advanced EOC regardless of HRD status,\nwhich was used as a stratiﬁcation factor. In the overall\npopulation, a signiﬁcant beneﬁt in median duration of PFS\nwas seen with niraparib over placebo (13.8 months v 8.2\nmonths; HR, 0.62; 95% CI, 0.50 to 0.76; P , .001). PFS\nwas also signiﬁcantly improved in those with HRD tumors\n(21.9 months v 10.4 months; HR, 0.43; 95% CI, 0.31 to\n0.59; P , .001). The extended median duration of PFS was\nalso observed in the niraparib group compared with the\nplacebo group (8.1 months v 5.4 months; HR, 0.68) in the\nsubgroup of patients with homologous recombination–\nproﬁcient tumors.\nThe PAOLA-124 trial is the ﬁrst phase III trial to examine the\nefﬁcacy of a PARPi\nwith bevacizumab as\nﬁrst-line\nmaintenance therapy in patients with advanced (FIGO\nstage III-IV), HGS and endometrioid EOC (other histologies\nif gBRCAm) with CR or PR (CR/PR) to standard platinum-\nbased chemotherapy given with bevacizumab. Patients,\nwho were not restricted by surgical outcome or gBRCA\nstatus, were randomly assigned to receive olaparib for up to\n24 months and bevacizumab for 15 months in total, or", "section": "Study quality was formally assessed for the fully published", "page_from": 6, "page_to": 6, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "3747eb5bda282fa29216557c4eb29ff6e8f092325c615c457570856a8cbf7b41"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000030", "text": "who were not restricted by surgical outcome or gBRCA\nstatus, were randomly assigned to receive olaparib for up to\n24 months and bevacizumab for 15 months in total, or\nplacebo. A statistically signiﬁcant improvement in PFS was\ndemonstrated in the ITT population compared with placebo\n(median PFS, 22.1 months v 16.6 months; HR, 0.59;\n95% CI, 0.49 to 0.72; P , .0001). Prespeciﬁed subgroup\nanalyses showed that patients with sBRCA mutations (HR,\n0.31; 95% CI, 0.20 to 0.47) and patients with positive HRD\nstatus (including g/sBRCA-mutated tumors; HR, 0.33;\n95% CI, 0.25 to 0.45) had the greatest PFS beneﬁts. No\nbeneﬁt was observed in patients with negative HRD status\n(16.6 v 16.2 months; HR, 1.00; 95% CI, 0.75 to 1.35). The\nrecent approval was limited to women with g/sBRCA and\nand/or genomic instability by Myriad myChoice CDx\n(Myriad Genetics, Salt Lake City, UT) and who have had\na CR/PR to chemotherapy plus bevacizumab combination.\nThe VELIA trial10 assessed the efﬁcacy of veliparib added to\nﬁrst-line chemotherapy with carboplatin and paclitaxel and\ncontinued as maintenance monotherapy in patients with\npreviously untreated, advanced, FIGO stage III-IV, HGS", "section": "Study quality was formally assessed for the fully published", "page_from": 6, "page_to": 6, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "d7a061efe36cb5cac3611dc89e02e1e771b12d29f3fe3f924ab272299c10b8a1"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000031", "text": "ﬁrst-line chemotherapy with carboplatin and paclitaxel and\ncontinued as maintenance monotherapy in patients with\npreviously untreated, advanced, FIGO stage III-IV, HGS\nEOC. In the overall population, the median PFS was\n23.5 months in the induction and maintenance veliparib\ngroup compared with 17.3 months in those receiving\nplacebo (HR, 0.68; 95% CI, 0.56 to 0.83; P , .001). In\npatients with gBRCA mutation, the median PFS was 34.7\nversus 22.0 months, respectively, in the veliparib com-\npared with the control group (HR, 0.44; 95% CI, 0.28 to\n0.68; P , .001). In the HRD cohort, the corresponding\nduration was 31.9 months and 20.5 months, respectively\n(HR, 0.57; 95% CI, 0.43 to 0.76; P , .001). In the ITT\npopulation, median PFS was 23.5 months versus 17.3\nmonths, respectively (HR, 0.68; 95% CI, 0.56 to 0.83; P ,\n.001). Stratiﬁcation was based on gBRCA status and was\nadded 14 months after initiation of the study, at which time\nthe study was more than half accrued. No beneﬁt was seen\nin patients with homologous-recombination–deﬁcient\nBRCA wild-type (BRCAwt) disease (HR, 0.74; 95% CI,\n0.52 to 1.06) or those with homologous-recombination–\nproﬁcient disease (HR, 0.81; 95% CI, 0.60 to 1.09).", "section": "Study quality was formally assessed for the fully published", "page_from": 6, "page_to": 6, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "d40a62e09f6c3ab5fad72a9d967413aad5beaecf16fbeaa88c848b8421cdc2ec"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000032", "text": "BRCA wild-type (BRCAwt) disease (HR, 0.74; 95% CI,\n0.52 to 1.06) or those with homologous-recombination–\nproﬁcient disease (HR, 0.81; 95% CI, 0.60 to 1.09).\nVeliparib is not approved in this setting and is not com-\nmercially available at this writing.\nTreatment of Recurrence Setting. Eight studies12,14,16,18,21,22,25,26\nwere identiﬁed that investigated PARPis as treatment for re-\ncurrence. Four open-label, phase II studies12,14,18,26 examined\nolaparib for patients with gBRCAm advanced EOC. Each study\nfound improved clinical beneﬁt with olaparib. Two single-arm\nstudies of rucaparib, ARIEL 225 and Study 10,16, also both\ndemonstrated improved PFS in measurable gBRCAm ovarian\ncancer.\nJournal of Clinical Oncology\n3473\nPARP Inhibitors in Ovarian Cancer\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158\nCopyright © 2025 American Society of Clinical Oncology. All rights reserved.", "section": "Study quality was formally assessed for the fully published", "page_from": 6, "page_to": 6, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "2072d25088209b537291aed5d74e58376ef3e50b822d7f1cc66763c6d8f925ba"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000033", "text": "TABLE 1. Clinical Trials Evaluating PARPis in EOC\nStudy (ClinicalTrials.gov identiﬁer)\nPatient Population\nPARPi\nFDA\nApproval\nDate\nTreatment Dosing\nIndication\nFront-line maintenance\nSOLO120\n(NCT01844986). Phase III,\nrandomized, double-blind, placebo\ncontrolled, multicenter study\nFemale patients with newly diagnosed, histologically\nconﬁrmed, high-risk advanced (FIGO stage III-IV)\nBRCAm, HGS or high-grade endometrioid ovarian cancer,\nprimary peritoneal cancer and/or fallopian tube cancer\nwho have completed ﬁrst-line platinum-based\nchemotherapy\nOlaparib\n12/2018\n300 mg BID (150 mg, 100 mg\ntablets)\nDeleterious germline OR somatic\nBRCAm and CR/PR to ﬁrst-line\nplatinum-based chemotherapy\nPatients must have clinical CR/PR and have no clinical\nevidence of disease progression\nPatients must be randomly assigned within 8 weeks of their\nlast dose of chemotherapy\nPRIMA (Gonzalez-Martin, 201913\nNCT02655016). Phase III,\nrandomized, double-blind, placebo\ncontrolled, multicenter study\nNewly diagnosed advanced ovarian cancer, regardless of\nBRCAm status\nNiraparib\n4/2020\n300 mg (3 3 100-mg capsules) for\npatients with a baseline body\nweight $ 77 kg and baseline\nplatelet count $ 150,000 mL", "section": "Patient Population", "page_from": 7, "page_to": 7, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "9bd73d8d0dc40f3f343f73fa86b0c87c0374ce8a0177003e22fbb6ffce35d578"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000034", "text": "BRCAm status\nNiraparib\n4/2020\n300 mg (3 3 100-mg capsules) for\npatients with a baseline body\nweight $ 77 kg and baseline\nplatelet count $ 150,000 mL\nCR/PR to ﬁrst-line platinum-based\nchemotherapy, regardless of\nBRCAm or HRD status\nHistologically conﬁrmed, advanced (FIGO stage III or IV),\nhigh-grade, predominantly serous or endometrioid\novarian cancer, fallopian tube cancer, or primary\nperitoneal cancer who have completed ﬁrst-line platinum-\nbased chemotherapy (neoadjuvant or adjuvant)\n200 mg (2 3 100-mg capsules) for\npatients with a baseline body\nweight , 77 kg or baseline\nplatelet count , 150,000 mL\nPatient must have clinical CR/PR after completing\nchemotherapy course\nPatient must be randomly assigned within 12 weeks of the\nﬁrst day of the last cycle of chemotherapy\nPAOLA-124\n(NCT02477644). Phase III,\nrandomized, double-blind,\nplacebo controlled, multicenter\nstudy\nNewly diagnosed ovarian cancer, primary peritoneal cancer,\nand/or fallopian tube cancer\nOlaparib 1\nbevacizumab\n5/2020\n300 mg BID (2 3 150-mg or\n3 3 100-mg tablets)\nCR/PR to ﬁrst-line chemotherapy and\nbevacizumab combination and\ng/sBRCA and/or genomic instability\nby Myriad myChoice CDx", "section": "Patient Population", "page_from": 7, "page_to": 7, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "15de9518236d026302b2fd7b1745d90bc397f195bfab84954ac3a58e79154ffd"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000035", "text": "Olaparib 1\nbevacizumab\n5/2020\n300 mg BID (2 3 150-mg or\n3 3 100-mg tablets)\nCR/PR to ﬁrst-line chemotherapy and\nbevacizumab combination and\ng/sBRCA and/or genomic instability\nby Myriad myChoice CDx\nHistologically conﬁrmed HGS, high-grade endometrioid or\nother epithelial nonmucinous ovarian cancer in a patient\nwith deleterious germline BRCA1/2 at an advanced stage\n(FIGO stage IIIB, IIIC, or IV)\nNon-BRCAm patients allowed if HGS\nCompleted ﬁrst-line platinum-taxane chemotherapy with\nbevacizumab prior to randomization\nPlatinum-taxane–based regimen must have consisted of\na minimum of four treatment cycles, including platinum,\nand a maximum of nine\nBevacizumab dose 15 mg/kg every 3 weeks up to a total of\n15 months\nPrior to randomization, patient’s disease must be NED or in\nCR/PR from her ﬁrst-line treatment\n(continued on following page)\n3474 © 2020 by American Society of Clinical Oncology\nVolume 38, Issue 30\nTew et al\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158\nCopyright © 2025 American Society of Clinical Oncology. All rights reserved.", "section": "Patient Population", "page_from": 7, "page_to": 7, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "ff21789c5d404dc38c1218b92c130f9c18a1fd7eeaa0003d132842aa28174c46"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000036", "text": "TABLE 1. Clinical Trials Evaluating PARPis in EOC (continued)\nStudy (ClinicalTrials.gov identiﬁer)\nPatient Population\nPARPi\nFDA\nApproval\nDate\nTreatment Dosing\nIndication\nVELIA10\n(NCT02470585). Phase III,\nrandomized, double-blind, placebo\ncontrolled, multicenter study\nHistologic diagnosis of FIGO stage III or IV epithelial ovarian,\nfallopian tube, or primary peritoneal carcinoma, with the\nappropriate tissue available for histologic evaluation\nVeliparib\nNone to\ndate\n150 mg BID for 2 weeks then\n(transition period) 400 mg BID\nStage III or IV HGS EOC\nHGS adenocarcinoma\nWilling to undergo testing for gBRCA\nTreatment of recurrent ovarian cancer\nStudy 4214\n(NCT01078662). Phase II, open\nlabel, nonrandomized,\nnoncomparative, multicenter study\nConﬁrmed germline loss-of-function BRCA1 or BRCA2\nmutation deemed deleterious or suspected\nOlaparib\n12/2014\n400 mg BID (50-mg capsules)\nDeleterious germline BRCA mutation,\n$ 3 prior systemic therapies\nPlatinum-resistant (relapse within 6 months of platinum\ntherapy) epithelial ovarian, primary peritoneal, or fallopian\ntube cancer (or unsuitable for additional platinum\ntherapy)\nSelect patients with breast, pancreatic, and hormone-", "section": "Patient Population", "page_from": 8, "page_to": 8, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "991d365190226327197736b8a36e14795ab140c1e3c13089514c6271cb06ce24"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000037", "text": "therapy) epithelial ovarian, primary peritoneal, or fallopian\ntube cancer (or unsuitable for additional platinum\ntherapy)\nSelect patients with breast, pancreatic, and hormone-\nrefractory prostate cancer were also eligible to participate\nOlaparib\n12/2014\n400 mg BID (50-mg capsules)\nDeleterious germline BRCA mutation,\n$ 3 prior systemic therapies\nGelmon et al12\n(NCT00679783). Phase II, open\nlabel, nonrandomized,\nnoncomparative, multicenter study\nHistologically conﬁrmed HGS and/or undifferentiated\ncarcinoma of ovary, fallopian tube, or peritoneum\nEstrogen, progesterone, and HER2-negative advanced\nadenocarcinoma of the breast\nOlaparib\n12/2014\n400 mg BID (50-mg capsules)\nDeleterious germline BRCA mutation,\n$ 3 prior systemic therapies\nKnown BRCA-positive breast cancer or ovarian cancer that is\nnot HGS or undifferentiated tubo-ovarian carcinoma\nCLIO Study26\n(NCT02822157). Phase II, open\nlabel, randomized, crossover study\nRecurrent epithelial carcinoma of the ovary, fallopian tube,\nor primary peritoneum\nOlaparib\n12/2014\n400 mg BID (50-mg capsules)\nDeleterious germline BRCA mutation,\n$ 3 prior systemic therapies\nAt least one previous line of chemotherapy\nLiu et al18", "section": "Patient Population", "page_from": 8, "page_to": 8, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "482e138d68ada6205e8e78b2e451d318a9177f3f6120e355c12b61cb9b9c886e"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000038", "text": "or primary peritoneum\nOlaparib\n12/2014\n400 mg BID (50-mg capsules)\nDeleterious germline BRCA mutation,\n$ 3 prior systemic therapies\nAt least one previous line of chemotherapy\nLiu et al18\n(NCT01116648). Phase II, open\nlabel, randomized study\nHistologically or cytologically grade 2 or 3 (high-grade)\npapillary-serous or endometrioid epithelial ovarian cancer,\nprimary peritoneal serous cancer, or fallopian tube\ncancer;\nOlaparib\n12/2014\n400 mg BID (50-mg capsules)\nDeleterious germline BRCA mutation,\n$ 3 prior systemic therapies\nParticipants with epithelial ovarian, primary peritoneal, or\nfallopian tube cancers of other high-grade histologies who\ncarry a known deleterious BRCA germline mutation\nKaye et al15\n(NCT 00628251). Phase II, open\nlabel, randomized study\nHistologically or cytologically conﬁrmed recurrent epithelial\novarian, primary peritoneal, or fallopian tube carcinoma\nand $ 1 measurable lesions according to RECIST\nOlaparib\n12/2014\n400 mg BID (50-mg capsules)\nDeleterious germline BRCA mutation,\n$ 3 prior systemic therapies\nConﬁrmed germline BRCA1/2 mutation, disease that\nrecurred or progressed within 12 months of the most\nrecent platinum-based chemotherapy regimen", "section": "Patient Population", "page_from": 8, "page_to": 8, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "33507215c75bd7101487d2274f494dbfb0b119c71bf1a23d7219dbae3aa5b8ab"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000039", "text": "$ 3 prior systemic therapies\nConﬁrmed germline BRCA1/2 mutation, disease that\nrecurred or progressed within 12 months of the most\nrecent platinum-based chemotherapy regimen\n(continued on following page)\nJournal of Clinical Oncology\n3475\nPARP Inhibitors in Ovarian Cancer\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158\nCopyright © 2025 American Society of Clinical Oncology. All rights reserved.", "section": "Patient Population", "page_from": 8, "page_to": 8, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "065c5e8a8c8a4f4f72d4acb19e78bb727789ea46a7ee3e034df293b2c8ba4103"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000040", "text": "TABLE 1. Clinical Trials Evaluating PARPis in EOC (continued)\nStudy (ClinicalTrials.gov identiﬁer)\nPatient Population\nPARPi\nFDA\nApproval\nDate\nTreatment Dosing\nIndication\nSOLO 322\n(NCT02282020). Phase III, open\nlabel, randomized, controlled,\nstudy\nHistologically diagnosed relapsed HGS ovarian cancer\n(including primary peritoneal and/or fallopian tube\ncancer) or high-grade endometrioid cancer. Patients are\neligible to undergo BRCA testing even if they have not yet\nhad recurrence or progression of disease . 6 months\n($ 183 d) after completion of their last platinum therapy\nOlaparib\n12/2014\n300 mg BID (150-mg tablets)\nDeleterious germline BRCA mutation,\n$ 3 prior systemic therapies\nDocumented germline mutation in BRCA1 and/or BRCA2\npredicted to be deleterious or suspected deleterious\nPatients must have received $ 2 prior platinum-based lines\nof chemotherapy\nPatients must be partially platinum sensitive or platinum\nsensitive\nStudy 1016\n(NCT01482715). Phase I/II, open-\nlabel, safety, pharmacokinetic, and\npreliminary efﬁcacy study\nKnown deleterious BRCA mutation (gBRCA or sBRCA)\nRucaparib\n12/2016\n600 mg BID (200-mg, 300-mg\ncapsules)\nDeleterious germline OR somatic\nBRCAm and $ 2 priors", "section": "Patient Population", "page_from": 9, "page_to": 9, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "718429da946707f2683b102d6adec7f1f857f32d5d406ac630fd1288f98273ab"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000041", "text": "preliminary efﬁcacy study\nKnown deleterious BRCA mutation (gBRCA or sBRCA)\nRucaparib\n12/2016\n600 mg BID (200-mg, 300-mg\ncapsules)\nDeleterious germline OR somatic\nBRCAm and $ 2 priors\nEvidence of measurable disease\nHistologically conﬁrmed diagnosis of high-grade epithelial\novarian, fallopian tube, or primary peritoneal cancer\nReceived $ 3 prior chemotherapy regimens and had\ndisease relapse\nARIEL 225\n(NCT01891344). Phase II, open-\nlabel, multicenter study\nHistologically conﬁrmed diagnosis of HGS or grade 2 or\ngrade 3 endometrioid epithelial ovarian, fallopian tube, or\nprimary peritoneal cancer. If mixed histology, . 50% of\nthe primary tumor had to be conﬁrmed to be HGS or\nendometrioid upon rereview by local pathology\nRucaparib\n12/2016\n600 mg BID (200-mg, 300-mg\ncapsules)\nDeleterious germline OR somatic\nBRCAm and $ 2 priors\nRelapsed/progressive disease\nReceived prior platinum-based therapy and had platinum-\nsensitive disease\nDisease had progressed $ 6 months after their most recent\nplatinum-based treatment\n(continued on following page)\n3476 © 2020 by American Society of Clinical Oncology\nVolume 38, Issue 30\nTew et al", "section": "Patient Population", "page_from": 9, "page_to": 9, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "24e347e1fe23a3cda46562bc466a758312e817f43687ee7f356feae7bbb21785"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000042", "text": "Disease had progressed $ 6 months after their most recent\nplatinum-based treatment\n(continued on following page)\n3476 © 2020 by American Society of Clinical Oncology\nVolume 38, Issue 30\nTew et al\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158\nCopyright © 2025 American Society of Clinical Oncology. All rights reserved.", "section": "Patient Population", "page_from": 9, "page_to": 9, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "0e6ef18c0b12eb5de0f7b39c5213e1ec1db939ba42b8af8d13775cd8d1868175"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000043", "text": "TABLE 1. Clinical Trials Evaluating PARPis in EOC (continued)\nStudy (ClinicalTrials.gov identiﬁer)\nPatient Population\nPARPi\nFDA\nApproval\nDate\nTreatment Dosing\nIndication\nQUADRA21\n(NCT02354586). Phase II,\nmulticenter, open-label, single arm\nstudy\nTumor HRD testing and blood gBRCAm status testing\nNiraparib\n10/2019\n300 mg daily\nRecurrent ovarian cancer treated with\n$ 3 prior chemotherapy regimens\nand cancer is associated with HRD\npositivity\nPatients must have histologically diagnosed high-grade\n(grade 2 or 3) serous epithelial ovarian, fallopian tube, or\nprimary peritoneal cancer with recurrent disease and\nmust have been previously treated with chemotherapy\nand experienced a response lasting $ 6 months to ﬁrst-\nline platinum-based therapy\nPatients must have completed three or four previous\nchemotherapy regimens, with the last chemotherapy\nregimen . 4 weeks before treatment initiation\nPatients must have measurable disease according to\nRECIST\nPatients must have formalin-ﬁxed, parafﬁn-embedded\ntumor samples available from the primary or recurrent\ncancer or agree to undergo fresh biopsy before study\ntreatment initiation\nMaintenance therapy, second-line and beyond\nStudy 1917,28", "section": "Patient Population", "page_from": 10, "page_to": 10, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "98ee2aa9199b66adff71aa0779f002de5b0bdd26f99e891819473e76f444e97b"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000044", "text": "tumor samples available from the primary or recurrent\ncancer or agree to undergo fresh biopsy before study\ntreatment initiation\nMaintenance therapy, second-line and beyond\nStudy 1917,28\n(NCT00753545). A phase II,\nrandomized, double-blind, placebo\ncontrolled, multicenter study\nFemale patients with histologically diagnosed recurrent\novarian or fallopian tube cancer or primary peritoneal\ncancer with HGS (grade 2 or 3) features\nOlaparib\n8/2017\n400 mg BID (50-mg capsules)a\nRecurrent ovarian cancer and CR/PR\nto platinum-based chemotherapy\nCompleted $ 2 courses of platinum-based chemotherapy\nand patient’s most recent regimen induced an objective\nresponse\nBRCAm status was not required (preplanned retrospective\nanalysis was conducted and published based on BRCAm\nstatus)\nPatients must be treated in the study within 8 weeks of\ncompletion of their ﬁnal dose of the platinum-containing\nregimen\nSOLO 223,27\n(NCT01874353). A phase III,\nrandomized, double-blind, placebo\ncontrolled, multicenter study\nRecurrent ovarian or fallopian tube or peritoneal cancer\nOlaparib\n8/2017\n300 mg BID (150-mg tablets)a\nRecurrent ovarian cancer and CR/PR\nto platinum-based chemotherapy\nPlatinum-sensitive disease", "section": "Patient Population", "page_from": 10, "page_to": 10, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "5456ac9dedf7cba863a8c78fc9d62889992aaa1b4992cbc9b980b042e7378aab"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000045", "text": "Recurrent ovarian or fallopian tube or peritoneal cancer\nOlaparib\n8/2017\n300 mg BID (150-mg tablets)a\nRecurrent ovarian cancer and CR/PR\nto platinum-based chemotherapy\nPlatinum-sensitive disease\nPatients had completed $ 2 courses of platinum-based\nchemotherapy with objective response\nRequired to have a predicted deleterious, or suspected\ndeleterious, BRCAm based on blood or tumor testing\n(continued on following page)\nJournal of Clinical Oncology\n3477\nPARP Inhibitors in Ovarian Cancer\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158\nCopyright © 2025 American Society of Clinical Oncology. All rights reserved.", "section": "Patient Population", "page_from": 10, "page_to": 10, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "b370aef0581e51e17b90775d8773b71445f171db030f08bed466d58ababf5e5c"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000046", "text": "TABLE 1. Clinical Trials Evaluating PARPis in EOC (continued)\nStudy (ClinicalTrials.gov identiﬁer)\nPatient Population\nPARPi\nFDA\nApproval\nDate\nTreatment Dosing\nIndication\nNOVA19\n(NCT01847274). A phase III,\nrandomized, double-blind, placebo\ncontrolled, multicenter study\nHistologically diagnosed ovarian cancer, fallopian tube\ncancer or primary peritoneal cancer\nNiraparib\n3/2017\n300 mg daily (100-mg capsules)\nRecurrent ovarian cancer and CR/PR\nto platinum-based chemotherapy\nHGS (or grade 3) histology or known to have gBRCAm\nReceived $ 2 previous courses of platinum-containing\ntherapy and had disease that was considered platinum\nsensitive (. 6 months between penultimate platinum\nregimen and progression of disease)\nResponded to last the platinum regimen and enrolled within\n8 weeks of the last platinum regimen\nARIEL 311\n(NCT01968213). A phase III,\nrandomized, double-blind, parallel\nassignment, multicenter study\nConﬁrmed diagnosis of HGS or endometrioid epithelial\novarian, primary peritoneal, or fallopian tube cancer\nRucaparib\n4/2018\n600 mg BID (200-mg, 300-mg\ncapsules)\nRecurrent ovarian cancer and CR/PR\nto platinum-based chemotherapy\nReceived $ 2 prior platinum-based treatments; last", "section": "Patient Population", "page_from": 11, "page_to": 11, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "ab7d5d65d4b2d199b0d42ade4d0e130cac630a9b008ac98dcc0e11a43d6fc5c7"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000047", "text": "Rucaparib\n4/2018\n600 mg BID (200-mg, 300-mg\ncapsules)\nRecurrent ovarian cancer and CR/PR\nto platinum-based chemotherapy\nReceived $ 2 prior platinum-based treatments; last\nplatinum-based regimen must have been administered\nimmediately before maintenance therapy\nReceived # 1 nonplatinum chemotherapy regimen. Prior\nhormonal therapy will not be counted as a nonplatinum\nregimen\nAt least a 6-month disease-free period after prior treatment\nwith the penultimate platinum-based chemotherapy and\nachieved a response\nFor the last chemotherapy course before study entry,\npatients must have received a platinum-based doublet\nchemotherapy regimen and have achieved a CR/PR and/\nor a GCIG CA-125 response\nAbbreviations: BID, twice daily; BRCAm, BRCA mutation; CGIC, Clinical Global Impression of Change; CR, complete response; EOC, epithelial ovarian, tubal, or primary peritoneal cancer; FDA, Food and\nDrug Administration; FIGO, International Federation of Obstetrics and Gynecology; gBRCAm, germline BRCA mutation; gBRCAwt, germline BRCA wild-type; g/sBRCAm, germline and/or somatic BRCA", "section": "Patient Population", "page_from": 11, "page_to": 11, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "56d4d3b60c45b83e9c332ac618695f6923fc78104639fb806ce8f725f6b69c45"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000048", "text": "Drug Administration; FIGO, International Federation of Obstetrics and Gynecology; gBRCAm, germline BRCA mutation; gBRCAwt, germline BRCA wild-type; g/sBRCAm, germline and/or somatic BRCA\nmutation; HGS, high-grade serous; HRD, homologous recombination deﬁciency; NED, without evidence of disease; PARPi, PARP inhibitor; PR, partial response; sBRCAm, somatic BRCA mutation.\naIn an attempt to improve dosing constraints of the capsule formulation, an alternative tablet formulation with improved bioavailability was developed to facilitate olaparib administration to patients.\nComparisons of the bioavailability of these two different oral formulations was investigated.29 Study 24 demonstrated that patients’ exposure after tablet doses $ 300 mg BID matched or exceeded that of the\napproved 400-mg BID capsule formulation (8 3 5-mg capsules BID). The 300-mg tablet dose BID was better tolerated than higher doses and it showed similar effectiveness in tumor shrinkage.\n3478 © 2020 by American Society of Clinical Oncology\nVolume 38, Issue 30\nTew et al\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158", "section": "Patient Population", "page_from": 11, "page_to": 11, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "7906aaa5f4b1b5c13bf49324027bb5c947c249cae736c33f6e19e03f6f0be8c0"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000049", "text": "3478 © 2020 by American Society of Clinical Oncology\nVolume 38, Issue 30\nTew et al\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158\nCopyright © 2025 American Society of Clinical Oncology. All rights reserved.", "section": "Patient Population", "page_from": 11, "page_to": 11, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "c35220034ae826bf9d11ba6508d176743b67f32a8cb8f831c3bf044824599205"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000050", "text": "TABLE 2. Newly Diagnosed Maintenance Setting\nOutcome\nSOLO120\nPRIMA13\nPRIMA13\nVELIA10\nVELIA10\nPAOLA-124\nITT Set\n(n 5 391)\nITT Set\n(n 5 733)\nHRD Population Subset\n(n 5 373)\nITT Set\n(n 5 757)\nBRCAm Subset\n(n 5 200)\nITT Set\n(n 5 806)\nOlaparib\n(n 5 260)\nPlacebo\n(n 5 131)\nNiraparib\n(n 5 487\nPlacebo\n(n 5 246)\nNiraparib\n(n 5 247\nPlacebo\n(n 5 126)\nVeliparib\n(n 5 382)\nControl\n(n 5 375)\nVeliparib\n(n 5 108)\nControl\n(n 5 92)\nOlaparib 1 Bev\n(n 5 537)\nPlacebo\n1 Bev\n(n 5 269)\nPFS\nData maturity: 51%\nData maturity: 59%\nRate, %\n60\n27\n—\n—\n—\n—\n48\n34\n—\n—\n52\n72\nMedian PFS, months\nNR\n13.8\n13.8\n8.2\n21.9\n10.4\n23.5\n17.3\n34.7\n22.0\n22.1\n16.6\nHR (95% CI)\n0.30 (0.23 to 0.41)\n0.62 (0.50 to 0.76)\n0.43 (0.31 to 0.59)\n0.68 (0.56 to 0.83)\n0.44 (0.2 8to 0.68)\n0.59 (0.49 to 0.72)\nTwo-sided P\n, .001\n, .001\n, .001\n, .001\n, .001\n, .0001\nPFS2\nData maturity: 31%\nData maturity: 39%\nRate, %\n75\n60\nNR\nNR\nNR\nNR\n—\n—\nMedian PFS2 (months)\nNR\n41.9\n32.3\n30.1\nHR (95% CI)\n0.50 (0.35 to 0.72)\n0.86 (0.69 to 1.09)\nTwo-sided P\n.0002\n—\nOS\nData maturity: 21%\nInterim analysis only\nData maturity 26%\nRate, %\n84\n80\n84\n77%\n91\n85\nNR\nNR\nNR\nMedian OS (months)\n—\n—\n—\nHR (95% CI)\n0.95 (0.60 to 1.53)\n0.70 (0.44 to 1.11)\n0.61 (0.27 to 1.39)\nTwo-sided P\n—", "section": "Outcome", "page_from": 12, "page_to": 12, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "a67922904a61a082cbdcc0ab205add8882b1395160f0337097035a7db7fddd5a"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000051", "text": "Interim analysis only\nData maturity 26%\nRate, %\n84\n80\n84\n77%\n91\n85\nNR\nNR\nNR\nMedian OS (months)\n—\n—\n—\nHR (95% CI)\n0.95 (0.60 to 1.53)\n0.70 (0.44 to 1.11)\n0.61 (0.27 to 1.39)\nTwo-sided P\n—\n—\nTFST\nData maturity: 59%\nRate, %\n—\n—\nNR\nNR\nNR\nNR\n—\n—\nMedian time (months)\n51.8\n15.1\n24.8\n18.5\nHR (95% CI)\n0.30 (0.22 to 0.40)\n0.59 (0.49 to 0.71)\nTwo-sided P\n—\n, .0001\nAbbreviations: —, not available; Bev, bevacizumab; BRCAm: breast cancer susceptibility gene mutation; HR, hazard ratio; HRD, homologous recombinant deﬁciency; ITT, intention to treat; NR, not\nreported; OS, overall survival; PFS, progression-free survival; PFS2, progression-free survival 2; TDT, time to study treatment discontinuation or death; TFST, time to ﬁrst subsequent therapy or death; TSST,\ntime to second subsequent therapy or death.\nJournal of Clinical Oncology\n3479\nPARP Inhibitors in Ovarian Cancer\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158\nCopyright © 2025 American Society of Clinical Oncology. All rights reserved.", "section": "Outcome", "page_from": 12, "page_to": 12, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "85cac4569095b47644499ac02db443ab23856f15fb4833a549a085ad3c534c83"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000052", "text": "TABLE 3. Treatment of Recurrent Ovarian Cancer\nStudy\nDose and\nFormulation\nData\nCutoff\nNo. of\nPatients\nTreatment and Comparator\nEfﬁcacy Outcomes\nPFS Rate\nand\nHR (95% CI) P\nMedian PFS\n(months) and\nHR (95% CI) P\nOS Rate and\nHR (95% CI)\nMedian OS\n(months)\nORR% and\nORR (95% CI) P\nStudy 4214\n400 mg BID,\ncapsule\nJuly 2012\nOvarian\ncancer\nsubset:\n193\nOlaparib (no comparator)\n54.6%\n7.0\n64.4%\n16.6\n31.1 ( 24.6 to 38.1)\nCLIO26\n300 mg BID,\ntablet\nDec\n2018\n100\nOlaparib v CTa\nNA\nOlaparib: 2.9\nNA\nNA\nOlaparib: 18%b\nCT: 3.4\nCT: 6%\nLiu et al18\n400 mg BID,\ncapsule\nMar 2014\n90\nOlaparib 1 cediranib v\nolaparib\nNA\nOlaparib 1\ncediranib: 17.7\nNA\nNA\nNA\nOlaparib: 9.0\n0.42 (0.23 to\n0.76)\nP 5 .005\nGelmon\net al12\n400 mg BID,\ncapsule\nMar 2010\nOvarian\ncancer\nsubset: 65\nOlaparib (no comparator)\nNA\nBRCAm\nnonserous:\n11.4c\nNA\nNA\nBRCAm nonserous:\n75%\nBRCAm serous:\n7.2c\nBRCAm serous:\n30.8%\nBRCAwt\nnonserous: 2.6c\nBRCAwt nonserous:\n0%\nBRCAwt serous:\n6.3c\nBRCAwt serous:\n25.6%\nKaye et al15\n200 or 400 mg\nBID, capsules\nPFS: Sep\n15,\n2009\n97\nOlaparib v PLD\n0.88 (0.51 to\n1.56) .66\nOlaparib 200 mg:\n6.5 (5.5 to\n10.1)\nPLD v 200:\n0.66 (0.27 to\n1.55)\nNA\nOlaparib 200 mg:\n25%\nOS: April\n30,\n2010\nOlaparib 400 mg:\n8.8 (5.4 to 9.2)", "section": "Study", "page_from": 13, "page_to": 13, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "7826bd561ec9958726b1f45840c1c551ce59abceff510c4830e3e016fab06456"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000053", "text": "15,\n2009\n97\nOlaparib v PLD\n0.88 (0.51 to\n1.56) .66\nOlaparib 200 mg:\n6.5 (5.5 to\n10.1)\nPLD v 200:\n0.66 (0.27 to\n1.55)\nNA\nOlaparib 200 mg:\n25%\nOS: April\n30,\n2010\nOlaparib 400 mg:\n8.8 (5.4 to 9.2)\nPLD v 40: 1.01\n(0.44 to\n2.27)\nOlaparib 400 mg:\n31%\nPLD: 7.1 (3.7 to\n10.7)\nPLD: 18%\nSOLO322\n300 mg BID,\ntablets\nOct 2018\n266\nOlaparib v chemotherapy\ntreatment of physician’s\nchoice\n0.62 (0.43 to\n0.91) .013\nOlaparib: 13.4\nNA\nNA\nOlaparib: 72.2%\nTPC: 9.2\nTPC: 51.4%\n2.53 (1.40 to 4.58)\n.002\nStudy 1016\n600 mg BID,\ncapsule\nNov 2015\n42\nRucaparib (no\ncomparator)\n59.5%\n7.8\nNA\nNA\n—\nARIEL 225\n600 mg BID,\ncapsule\nJan 2016\n206\nRucaparib (no\ncomparator)\nBRCAm: 50%\nBRCAm: 12.8\nNA\nNA\nBRCAm: 32%\nLOH low: 10%\nLOH low: 5.2\nLOH low: 7%\n0.27 (0.16 to\n0.44)\n, .0001\nLOH high: 5.7\nP , .0001\nLOH low: 5.2\nLOH high: 24%\nLOH high:\n28%\nLOH low: 7%\nLOH low: 10%\nP 5 .0033\n0.62 (0.42 to\n0.90) .011\nQUADRA21\n300 mg, daily\nApr 2018\n463\nNiraparib (no comparator)\nNA\n5.5\nNA\n17.2\n28%\nMedian duration of\nresponse:\n9.2 months\nAbbreviations: BID, twice daily; CT, chemotherapy; HR, hazard ratio; LOH, loss of heterozygosity; NA, not available; OR, odds ratio; ORR, objective", "section": "Study", "page_from": 13, "page_to": 13, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "85b6dfb8a5dd54076b57df2aeecbb9e7385e9315f1908c367fc649e34eee5c7e"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000054", "text": "NA\n17.2\n28%\nMedian duration of\nresponse:\n9.2 months\nAbbreviations: BID, twice daily; CT, chemotherapy; HR, hazard ratio; LOH, loss of heterozygosity; NA, not available; OR, odds ratio; ORR, objective\nresponse rate; OS, overall survival; PFS, progression-free survival; PLD, pegylated liposomal doxorubicin; TPC, treatment of physician’s choice.\naPhysician’s choice chemotherapy that includes carboplatin 1 gemcitabine or carboplatin 1 paclitaxel or carboplatin 1 liposomal doxorubicin or liposomal\ndoxorubicin every 4 weeks or topotecan or paclitaxel weekly.\nbORR for olaparib was 38% (n 5 5 of 13) in patients with gBRCAm and 13% (n 5 7 of 54) in patients with gBRCAwt.\ncMedian PFS was reported in days and converted to months for the table.\n3480 © 2020 by American Society of Clinical Oncology\nVolume 38, Issue 30\nTew et al\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158\nCopyright © 2025 American Society of Clinical Oncology. All rights reserved.", "section": "Study", "page_from": 13, "page_to": 13, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "9761e2503ae5459556cf02e9393c6c16e9803f049fdde8af4f4ce13d9f3c4c43"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000055", "text": "TABLE 4. Maintenance Therapy for Recurrent Platinum-Sensitive Disease\nOutcome\nSOLO223,27\n(tablet formulation,\n300 mg BID)\nSTUDY 1917,28\n(capsule\nformulation, 400 mg\nBID)\nNOVA19\n(capsule\nformulation, 300 mg\ndaily)\nNOVA19\ncapsule formulation,\n300 mg daily)\nARIEL 311\n(capsule formulation,\n600 mg BID)\nARIEL 311\n(capsule formulation,\n600 mg BID)\nDCO Sept 2016/Feb\n2020 for OS\nFull Analysis Set\n(N 5 295)\nDCO 2012/2015\nBRCAm Subset\n(n 5 136)\nDCO June 2016\ngBRCAm Subset\n(n 5 203)\nDCO June 2016\nNon-gBRCAm Subset\n(n 5 350)\nDCO April 2017\nBRCAm Subset\n(n 5 196)\nDCO April 2017\nITT\n(n 5 207)\nOlaparib\n(n 5 196)\nPlacebo\n(n 5 99)\nOlaparib\n(n 5 74)\nPlacebo\n(n 5 62)\nNiraparib\n(n 5 138)\nPlacebo\n(n 5 65)\nNiraparib\n(n 5 234)\nPlacebo\n(n 5 116)\nRucaparib\n(n 5 130)\nPlacebo\n(n 5 66)\nRucaparib\n(n 5 141)\nPlacebo\n(n 5 66)\nPFS\nMedian PFS\n(months)\n19.1\n5.5\n11.2\n4.3\n21.0\n5.5\n9.3\n3.9\n16.6\n5.4\n10.8\n5.4\nHR (95% CI)\n0.30 (0.22 to 0.41)\n0.18 (0.10 to 0.31)\n0.27 (0.17 to 0.41)\n0.45 (0.34 to 0.61)\n0.23 (0.16 to 0.34)\n0.37 (0.30 to 0.45)\nTwo-sided P\n, .0001\n, .00001\n, .0001\n, .001\n, .001\n, .0001\nPFS2\nMedian PFS2\n(months)\nNR\n18.4\nNA\nNA\n25.8\n19.5\n18.6\n15.6\nNA\nNA\nNA\nNA\nHR (95% CI)\n0.50 (0.34 to 0.72)\nNA\n0.48 (0.28 to 0.82)", "section": "Outcome", "page_from": 14, "page_to": 14, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "a576e79a1bf1de1d0c7896135cc55f66facfdf34728cffb4a26c297c9fdbb04c"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000056", "text": "Two-sided P\n, .0001\n, .00001\n, .0001\n, .001\n, .001\n, .0001\nPFS2\nMedian PFS2\n(months)\nNR\n18.4\nNA\nNA\n25.8\n19.5\n18.6\n15.6\nNA\nNA\nNA\nNA\nHR (95% CI)\n0.50 (0.34 to 0.72)\nNA\n0.48 (0.28 to 0.82)\n0.69 (0.49 to 0.96)\nNA\nNA\nTwo-sided P\n.0002\nNA\n.006\n.03\nNA\nNA\nOS\nMedian OS\n(months)\n51.7\n38.8\n34.9\n30.2\nNA\nNA\nNA\nNA\nNA\nNA\nNA\nNA\nHR (95% CI)\n0.74 (0.54 to 1.00)\n0.62 (0.41 to 0.94)\nNA\nNA\nNA\nNA\nTwo-sided P\n.054\n.02480\nNA\nNA\nNA\nNA\nORR (CR1PR)\nNo. of events:\ntotal no. of\npatients (%)\nNA\nNA\n7:57\n(12)\n2:48 (4)\nNA\nNA\nNA\nNA\n15:40\n(37.5)\n2:23\n(8.7)\n26:141\n(18.4)\n5:66\n(7.6)\nHR (95% CI)\nNA\n3.36 (0.75 to\n23.72)\nNA\nNA\nNR\nNR\nTwo-sided P\nNA\n.12\nNA\nNA\nTDT\nMedian time\n(months)\n19.4\n5.6\n11.0\n4.6\nNA\nNA\nNA\nNA\nNA\nNA\nNA\nNA\nHR (95% CI)\n0.31 (0.23 to 0.42)\n0.36 (0.25 to 0.52)\nNA\nNA\nNA\nNA\nTwo-sided P\n, .0001 (nominal P\nvalue)\n, .00001\nNA\nNA\nNA\nNA\nTFST\nMedian time\n(months)\n27.9\n7.1\n15.6\n6.2\n21.0\n8.4\n11.8\n7.2\nNA\nNA\nNA\nNA\nHR (95% CI)\n0.28 (0.21 to 0.38)\n0.32 (0.22 to 0.48)\n0.31 (0.21 to 0.48)\n0.55 (0.41 to 0.72)\nNA\nNA\nTwo-sided P)\n, .0001\n, .00001\n, .001\n, .001\nNA\nNA\nTSST\nMedian time\n(months)\nNR\n18.2\n22.0\n15.3\nNA\nNA\nNA\nNA\nNA\nNA\nNA\nNA\nHR (95% CI)\n0.37 (0.26 to 0.53)\n0.41 (0.28 to 0.62)\nNA\nNA\nNA\nNA\nTwo-sided P\n, .0001\n.00001\nNA", "section": "Outcome", "page_from": 14, "page_to": 14, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "6c85cbc44a641a32c1d22a976df21128fd8790ebea035561bc8506c899c5bd97"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000057", "text": ", .0001\n, .00001\n, .001\n, .001\nNA\nNA\nTSST\nMedian time\n(months)\nNR\n18.2\n22.0\n15.3\nNA\nNA\nNA\nNA\nNA\nNA\nNA\nNA\nHR (95% CI)\n0.37 (0.26 to 0.53)\n0.41 (0.28 to 0.62)\nNA\nNA\nNA\nNA\nTwo-sided P\n, .0001\n.00001\nNA\nNA\nNA\nNA\nAbbreviations: BID, twice daily; BRCAm, breast cancer susceptibility gene mutation; CR, complete response; DCO, data cutoff; gBRCAm, germline breast\ncancer susceptibility gene mutation; HR, hazard ratio; ITT, intention to treat; NA, not available; NR, not reached; PFS, progression-free survival; PFS2,\nprogression-free survival 2; OS, overall survival; ORR, objective response rate; PR, partial response; TDT, time to study treatment discontinuation or death;\nTFST, time to ﬁrst subsequent therapy or death; TSST, time to second subsequent therapy or death.\nJournal of Clinical Oncology\n3481\nPARP Inhibitors in Ovarian Cancer\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158\nCopyright © 2025 American Society of Clinical Oncology. All rights reserved.", "section": "Outcome", "page_from": 14, "page_to": 14, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "52c8748f67191326ea0bed1be869d043c360ae855623b93ebb961ca09b62ea0d"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000058", "text": "The SOLO3 trial22 assessed the efﬁcacy of olaparib com-\npared with chemotherapy of physician’s choice in patients\nwith platinum-sensitive, relapsed, HGS or endometrioid\nEOC with gBRCAm. Patients were stratiﬁed by type of\nchemotherapy received, prior lines of chemotherapy (2-\n3 v $ 4), and platinum-free interval (6-12 v . 12 months).\nThe objective response rate (ORR) by independent central\nreview was 72% with olaparib versus 51% with treatment of\nphysician’s choice (odds ratio, 2.53; 95% CI, 1.40 to 4.58;\nP 5 .002). The HR for PFS independent central review was\n0.62 (95% CI, 0.43 to 0.91; P 5 .013), with a median of\n13.4 months with olaparib versus 9.2 months with che-\nmotherapy. The PFS by investigator assessment was 0.49\n(95% CI, 0.35 to 0.70; P , .001), with a median of 13.2\nversus 8.5 months, respectively.\nThe QUADRA trial,21 a single-arm nonrandomized trial,\nevaluated niraparib in adult patients with relapsed, HGS\nepithelial ovarian, fallopian tube, or primary peritoneal\ncancer who had been treated with $ 3 previous che-\nmotherapy regimens. The trial met its primary end point of\noverall response, with 13 of 47 patients (28%; 95% CI,", "section": "Outcome", "page_from": 15, "page_to": 15, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "6b752968011499afcadeba42c1e0ff77f98a5084abc75760bd859f69abb0bfa0"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000059", "text": "cancer who had been treated with $ 3 previous che-\nmotherapy regimens. The trial met its primary end point of\noverall response, with 13 of 47 patients (28%; 95% CI,\n15.6% to 42.6%; one-sided P 5 .00053) with HRD-positive\ntumors who received three to four previous anticancer\ntherapies and were sensitive to the most recent platinum-\nbased therapy. The median duration of PFS in this pop-\nulation was 5.5 months (95% CI, 3.5 to 8.2 months), and\nmedian duration of response was 9.2 months (95% CI,\n5.9–not estimable months). A total of 38 of 456 patients\n(8%) in the modiﬁed per-protocol population achieved an\noverall response. The observed median OS in the modiﬁed\nper-protocol population was 17.2 months (95% CI, 14.9 to\n19.8 months).\nSecond-line and beyond maintenance setting. Four trials\ninvestigated the efﬁcacy of PARPis in maintenance therapy\nin recurrent disease.11,17,19,23,28\nStudy 1917 accrued patients with platinum-sensitive, re-\ncurrent, high-grade EOC who had received $ 2 prior lines of\nplatinum-based chemotherapy and had a CR/PR to the\nmost recent treatment, demonstrating olaparib mainte-\nnance signiﬁcantly improved PFS (median 8.4 v 4.8", "section": "Outcome", "page_from": 15, "page_to": 15, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "23260cb08d8013f7e72421572ad9ef279d1b41c89624e05842236cd03c27679a"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000060", "text": "platinum-based chemotherapy and had a CR/PR to the\nmost recent treatment, demonstrating olaparib mainte-\nnance signiﬁcantly improved PFS (median 8.4 v 4.8\nmonths; HR, 0.35; 95% CI, 0.25 to 0.49; P , .001).\nTABLE 5. Grade 3/4 Adverse Events in Randomized Controlled Trials\nGrade 3/4 Adverse Events (%)\nReference\nIntervention\nNo. of Patients\nFatiguea\nNausea/Vomiting\nAnemiab\nNeutropeniac\nThrombocytopenia\nStudy 1917\nOlaparib\n136\n7.3\n4.4\n5.1\n4\nNR\nPlacebo\n129\n3.0\n, 1\n, 1\n, 1\nSOLO223\nOlaparib\n195\n4.1\n5.2\n19.5\n5.1\n1\nPlacebo\n99\n2.0\n1.0\n2.0\n4.0\nNR\nSOLO120\nOlaparib\n260\n4\n1.1\n22\n9\n1\nPlacebo\n130\n2\n1\n2\n5\n2\nSOLO322\nOlaparib\n178\n4.5\n2.2\n21.3\n9.6\n3.9\nNonplatinum-based chemotherapy\n88\n1.3\n3.9\n0\n15.8\n2.6\nStudy 1016\nRucaparib\n42\n26.2\n14.3\n38.1\n16.7\n2.4\nARIEL 225\nRucaparib\n204\n9\n6\n22\n8\n2\nARIEL 311\nRucaparib\n372\n7\n8\n19\n7\n5\nPlacebo\n189\n3\n2\n1\n2\n0\nNOVA19\nNiraparib\n367\n8.2\n4.9\n25.3\n19.6\n33.8\nPlacebo\n179\n0.6\n1.7\n0\n1.7\n0.6\nPRIMA13\nNiraparib\n484\n1.9\n2.0\n31\n12.8\n28.7\nPlacebo\n244\n0.4\n1.6\n1.6\n1.2\n0.4\nVELIA10\nVeliparib combination\n376\n5\n8\n41\n62\n31\nVeliparib throughout\n377\n8\n12\n38\n58\n28\nControl\n371\n3\n5\n26\n49\n8\nPAOLA-124\nOlaparib 1 bev\n535\n5\n4\n17\n6\n2\nPlacebo 1 bev\n267\n1\n3\n, 1\n3\n, 1", "section": "Outcome", "page_from": 15, "page_to": 15, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "893a5d88c9f9c1c01fd9780ee17f50e1661d9a49492b40e63f31f2e8afd1607d"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000061", "text": "1.6\n1.6\n1.2\n0.4\nVELIA10\nVeliparib combination\n376\n5\n8\n41\n62\n31\nVeliparib throughout\n377\n8\n12\n38\n58\n28\nControl\n371\n3\n5\n26\n49\n8\nPAOLA-124\nOlaparib 1 bev\n535\n5\n4\n17\n6\n2\nPlacebo 1 bev\n267\n1\n3\n, 1\n3\n, 1\nAbbreviations: bev, bevacizumab; NR, not reported.\naIncludes patients with fatigue and patients with asthenia.\nbIncludes patients with anemia, decreased hemoglobin, hematocrit, and red blood cell count.\ncIncludes patients with neutropenia; febrile neutropenia; neutropenic sepsis; decreased neutrophil and granulocytes; granulocytopenia.\n3482 © 2020 by American Society of Clinical Oncology\nVolume 38, Issue 30\nTew et al\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158\nCopyright © 2025 American Society of Clinical Oncology. All rights reserved.", "section": "Outcome", "page_from": 15, "page_to": 15, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "dc178a879ec7121222d6ba677334d36dd492c7ba5bf3d999b5a2f3d650e55d82"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000062", "text": "Retrospective testing for g/sBRCA mutations was per-\nformed for all patients, and it was determined that 51% of\nparticipants had g/sBRCAm. Patients with gBRCAm tumors\nwere reported to have a 6.9-month prolongation of median\nPFS (11.2 compared with 4.3 months in the olaparib and\nplacebo arms, respectively). Additional analyses in the\nBRCAwt population also demonstrated a statistically sig-\nniﬁcant difference in favor of the olaparib maintenance\ntreatment arm. However, the magnitude of difference was\nlower when compared with the population of patients with\ngBRCAm (7.4 months v 5.5 months; HR, 0.54; 95% CI,\n0.34 to 0.85; P 5 .0075). Analyses for OS28 showed\na slight survival advantage with olaparib over placebo in\nthe ITT population (media OS, 29.8 v 27.8 months, re-\nspectively; HR, 0.73; 95% CI, 0.55 to 0.95; P 5 .02) after\na median follow-up of 78 months. In the gBRCAm\npopulation, OS was 34.9 months versus 30.2 months in\nthe olaparib-treated patients compared with those re-\nceiving placebo, respectively. The median improvement\nin OS was 4.7 months longer for olaparib versus placebo\n(HR, 0.62; 95% CI, 0.42 to 0.93). It is notable that", "section": "Outcome", "page_from": 16, "page_to": 16, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "2c2df9b64dba60a859aae5596ad5a40415d378b01253dbb6fdecaf98a2b25fa1"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000063", "text": "ceiving placebo, respectively. The median improvement\nin OS was 4.7 months longer for olaparib versus placebo\n(HR, 0.62; 95% CI, 0.42 to 0.93). It is notable that\nthe threshold was not set to determine statistical signif-\nicance for OS in the BRCAm subgroup; therefore, the\nreported P values are nominal.\nThe SOLO2 trial23 investigated olaparib monotherapy in\npatients with platinum-sensitive, recurrent, g/sBRCA1/2m\nEOC who had received $ 2 lines of chemotherapy and\ndemonstrated a CR/PR to the most recent line of treatment.\nResults showed a statistically signiﬁcant improvement in\nthe median PFS for olaparib over placebo of 13.6 months\n(median PFS, 19.1 v 5.5 months), translating to a 70%\nreduction in risk of disease progression or death with\nolaparib versus placebo (HR, 0.30; 95% CI, 0.22 to 0.41;\nP , .0001). The proportion of patients who had not ex-\nperienced disease progression at 12 months was\n3.1 times greater in the olaparib group than in the placebo\ngroup (65.1% v 20.9%, respectively). Moreover, the\nproportion of patients who remained progression free at the\n2-year mark was 2.8 times greater in the olaparib group than\nin the placebo group (43.0% v 15.1%, respectively). A", "section": "Outcome", "page_from": 16, "page_to": 16, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "05148a6f153af9854755f956c01e69af52ed62092eb6aa2e77627df4107a046b"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000064", "text": "proportion of patients who remained progression free at the\n2-year mark was 2.8 times greater in the olaparib group than\nin the placebo group (43.0% v 15.1%, respectively). A\npreplanned, ﬁnal, OS analysis with data maturity of\n61% demonstrated that olaparib extended OS by approxi-\nmately 13 months compared with placebo (38.8 v 51.7\nmonths; HR, 0.74; 95% CI, 0.54 to 1.00; P 5 .054) in the full\nanalysis set.27 In the prespeciﬁed sensitivity analysis of\npatients with germline BRCA mutation, OS was extended by\n15 months with olaparib compared with placebo (37.4 v\n52.4 months; HR, 0.71; 95% CI, 0.52 to 0.97; P 5 .031).27\nChemotherapy\n± bev\nChemotherapy\nRecommended\nMay be used\nStandard of\nCare\nDisease Life\nCycle\nPARPi\nRecommendations\nPARPi\nmaintenance\nin stages III-IV\nPARPi treatment for\ngermline or somatic\nBRCAm\nPARPi\ntreatment\nPARPi\nmaintenance\nCT ± bev → PARPi + bev\nOR\nOR\nOR\nOR\nCT ±\nbev\nBev\nmaintenance\nPlatinum\ncombination +\nbev\nBev\nmaintenance\nChemotherapy\nDiagnosis\nEnd first-\nline\ntherapy\nPlatinum-\nsensitive\nrecurrence\nEnd\nsecond-\nline\ntherapy\nPlatinum-\nresistent\nrecurrence", "section": "Outcome", "page_from": 16, "page_to": 16, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "6291b0c8102ab15471775ddf15194b9e8aa71c5abb9b1fe028a71e5f2ba5a005"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000065", "text": "bev\nBev\nmaintenance\nPlatinum\ncombination +\nbev\nBev\nmaintenance\nChemotherapy\nDiagnosis\nEnd first-\nline\ntherapy\nPlatinum-\nsensitive\nrecurrence\nEnd\nsecond-\nline\ntherapy\nPlatinum-\nresistent\nrecurrence\nFIG 1. PARP inhibitor (PARPi) use opportunities in women who are PARPi na¨ıve. Recommendations are color coded: Orange indicates rec-\nommendations; green indicates considerations for use. Figure 1 should not be interpreted as justiﬁcation for PARPi use in . 1 of these settings. Bev,\nbevacixumab; CT, carboplatin and paclitaxel; BRCAm: BRCA1/2 mutation.\nJournal of Clinical Oncology\n3483\nPARP Inhibitors in Ovarian Cancer\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158\nCopyright © 2025 American Society of Clinical Oncology. All rights reserved.", "section": "Outcome", "page_from": 16, "page_to": 16, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "11e86ebf080bc3fa50895b3a0ee79489b033e33c3b0bc3f264e2707f995b2f81"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000066", "text": "The NOVA trial19 evaluated niraparib in patients with\nplatinum-sensitive, recurrent EOC who had a CR/PR after\n$ 2 prior lines of platinum-based chemotherapy. Niraparib\nmaintenance signiﬁcantly improved PFS, compared with\nplacebo, irrespective of the gBRCAm (21.0 v 5.5 months;\nHR, 0.27; 95% CI, 0.17 to 0.41; P , .001) or HRD status\n(HRD plus BRCAwt: 12.9 v 3.8 months; HR, 0.38; 95% CI,\n0.24 to 0.59; P , .001) and in the overall BRCAwt group\n(9.3 v 3.9 months; HR, 0.45; 95% CI, 0.34 to 0.61;\nP , .001).\nThe ARIEL 3 trial11 for rucaparib included three populations\nfor step-down analysis of the primary end point, PFS: tumor\nBRCA-mutant (germline or somatic); HRD-positive, which\nincluded the gBRCAm group along with those with a pos-\nitive HRD score (including BRCAwt with high [$ 16%]\ngenomic loss of heterozygosity; and the ITT [all-comer]\npopulation), which, again, included the gBRCAm and\nHRD-positive groups.11 PFS was signiﬁcantly improved with\nrucaparib versus placebo in all three populations, although\nthe most robust clinical outcomes were seen in the\ngBRCAm subgroup.\nQuality of Life\nSeven RCTs10,13,17,19,20,23,24 reported quality-of-life (QOL)", "section": "The NOVA trial19 evaluated niraparib in patients with", "page_from": 17, "page_to": 17, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "2e8c4fff5a59987c9c0e37fc0fb7d6e99b860cd754b6dbfbe7d8b6bad90e7d34"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000067", "text": "the most robust clinical outcomes were seen in the\ngBRCAm subgroup.\nQuality of Life\nSeven RCTs10,13,17,19,20,23,24 reported quality-of-life (QOL)\nend points with high completion rates. Analyses of these\npatient-reported outcomes found, in general, the majority of\nQOL scores numerically favored treatment with PARPis.\nHowever, few signiﬁcant differences were observed be-\ntween the treatment groups. In the absence of disease-\nrelated symptoms for trials occurring in the maintenance\nsetting, that comparable scores were observed over time\nacross and between treatment groups suggests that women\nmaintain QOL during their PARPi treatment when com-\npared with placebo. PARPis did not appear to incur ad-\nditional burden or negatively impact HRQoL either during\ntreatment or long-term follow up.\nAdverse Events\nThe proportion of patients who experienced any AEs was\nhigher in patients receiving PARPis than those in the\ncomparator groups (Table 5). Anemia was the most\ncommon grade $ 3 AE in the PARPi group, reported to\nrange from 5% to 22% with olaparib,17,20,22,23 19% to\n38% with rucaparib,11,16,25 25% to 31% with niraparib,13,19\n38% to 41% with veliparib combination therapy,10 and", "section": "The NOVA trial19 evaluated niraparib in patients with", "page_from": 17, "page_to": 17, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "31fd58f3bd6a2e6c10a7aead44afa8ade878e8997a80eaf2bdf6abd9c1ac7daa"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000068", "text": "range from 5% to 22% with olaparib,17,20,22,23 19% to\n38% with rucaparib,11,16,25 25% to 31% with niraparib,13,19\n38% to 41% with veliparib combination therapy,10 and\n17% with olaparib plus bevacizumab.24 The incidence of\nother AEs such as fatigue/asthenia, nausea, and vomiting\nwere much lower (Table 5). Hematologic toxicities were\nmore frequent with veliparib combination and niraparib\nmonotherapy than with treatment with other PARPis. Grade\n3 or higher neutropenia occurred in up to 62% of patients\nreceiving veliparib combination treatment10 and in\n19.6% of patient treated with niraparib.19 Similarly,\nthrombocytopenia was reported in up to 31% of patients\nreceiving veliparib combination treatment and in 34% of\nthose treated with niraparib. However, in the NOVA trial,\nthrombocytopenia was transient and treatment discontin-\nuations were not attributed to these hematologic events.19\nThe most prominent grade 3/4 AEs with rucaparib included\nfatigue (26.2%) and nausea and vomiting (14%).16 Overall,\nmanagement of AEs, for the majority of cases, were han-\ndled with appropriate dose reductions and delays.\nRECOMMENDATIONS\nNOTE: These recommendations pertain only to patients", "section": "The NOVA trial19 evaluated niraparib in patients with", "page_from": 17, "page_to": 17, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "3312880d5b0ec44da4b0b189965390f43c5183614653caa4e484ab702319775a"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000069", "text": "management of AEs, for the majority of cases, were han-\ndled with appropriate dose reductions and delays.\nRECOMMENDATIONS\nNOTE: These recommendations pertain only to patients\nwith EOC who have not previously received a PARPi. The\nrecommendations are based on clinical trial results and\nFDA approvals and do not necessarily capture regulatory\napproval in other jurisdictions.\nCLINICAL QUESTION 1\nRepeating PARPi\nShould PARPi therapy for EOC be repeated over the course\nof treatment?\nRecommendation 1.0\nRepeating PARPi therapy in the treatment of EOC is not\nrecommended at this time. Consideration should be made\nas to the best time in the life cycle of an individual patient’s\nEOC in which to use PARPi; clinical trial participation is\nencouraged (Type: informal consensus, beneﬁts outweigh\nharms; Evidence quality: insufﬁcient; Strength of recom-\nmendation: strong).\nLiterature review and analysis.\nTrials investigating the\nredeployment of PARPis are currently underway. Enroll-\nment began in 2017 for the OReO/ENGOT Ov-38 trial\n(ClinicalTrials.gov identiﬁer: NCT03106987), a random-\nized, placebo-controlled, multicenter trial of olaparib\nmaintenance retreatment in patients with nonmucinous", "section": "The NOVA trial19 evaluated niraparib in patients with", "page_from": 17, "page_to": 17, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "f572f2609533923d1fee2817ec65364617bce07a680c155129220f9bf1f80f80"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000070", "text": "(ClinicalTrials.gov identiﬁer: NCT03106987), a random-\nized, placebo-controlled, multicenter trial of olaparib\nmaintenance retreatment in patients with nonmucinous\nEOC, and a CR/PR to their most recent platinum-based\nchemotherapy. Eligibility requires prior receipt of mainte-\nnance PARPi therapy. Random assignment to olaparib or\nmatching placebo is split across two cohorts (approximately\n416 patients): patients with a known BRCAm in cohort 1;\npatients with BRCAwt in cohort 2. The primary end point is\ninvestigator-assessed PFS and the study is expected to be\ncompleted in 2021.\nCLINICAL QUESTION 2\nNewly Diagnosed Ovarian Cancer\nFor which patients with newly diagnosed EOC are PARPi\nrecommended?\na. What are the histologic types of EOC for which PARPis\nare recommended?\nb. What are the biomarker subsets for which PARPis are\nrecommended?\nRecommendation 2.0\nPARPis are not recommended for use in initial treatment of\nearly-stage (ie, stage I-II) EOC, because there is insufﬁcient\nevidence to support use in this population. (Type: informal\n3484 © 2020 by American Society of Clinical Oncology\nVolume 38, Issue 30\nTew et al", "section": "The NOVA trial19 evaluated niraparib in patients with", "page_from": 17, "page_to": 17, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "2f481a5509c7cc0dc43858600c32b72a00c6347e0a8432e5bf51f50bfff80d3d"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000071", "text": "evidence to support use in this population. (Type: informal\n3484 © 2020 by American Society of Clinical Oncology\nVolume 38, Issue 30\nTew et al\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158\nCopyright © 2025 American Society of Clinical Oncology. All rights reserved.", "section": "The NOVA trial19 evaluated niraparib in patients with", "page_from": 17, "page_to": 17, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "0bf5104f3a30f47001026dd4a214d84730f6088a7fb7584ee26c0c5faa3a7441"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000072", "text": "consensus; beneﬁts outweigh harms; Evidence quality:\ninsufﬁcient; Strength of recommendation: strong)\nRecommendation 2.1\nWomen with newly diagnosed stage III-IV EOC whose\ndisease is in CR/PR to ﬁrst-line, platinum-based chemo-\ntherapy should be offered PARPi maintenance therapy with\nolaparib (for those with germline or somatic pathogenic or\nlikely pathogenic variants in BRCA1 and BRCA2 genes) or\nniraparib (all women) for treatment of high-grade serous\nor endometrioid ovarian cancer.\n• PARPi maintenance therapy should consist of olaparib\n(300 mg orally every 12 hours for 2 years) or niraparib\n(200-300 mg orally daily for 3 years). Longer duration\ncould be considered in selected individuals.\n(Type: evidence based, beneﬁts outweigh harms; Evidence\nquality: high; Strength of recommendation: strong).\nRecommendation 2.2\nThe addition of olaparib to bevacizumab maintenance may\nbe offered to patients who have stage III-IV, high-grade\nserous or endometrioid ovarian cancer and germline or\nsomatic pathogenic or likely pathogenic variants in BRCA1\nor BRCA2 genes and/or genomic instability, as determined\nby Myriad myChoice CDx, and who have a CR/PR to", "section": "Women with newly diagnosed stage III-IV EOC whose", "page_from": 18, "page_to": 18, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "6518c2971dc3f9874983b763d6bc214bd8ef2c86788065ecd5ca004432a08c01"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000073", "text": "somatic pathogenic or likely pathogenic variants in BRCA1\nor BRCA2 genes and/or genomic instability, as determined\nby Myriad myChoice CDx, and who have a CR/PR to\nchemotherapy plus bevacizumab combination (Type: evi-\ndence based, beneﬁts outweigh harms; Evidence quality:\nstrong; Strength of recommendation: strong).\nRecommendation 2.3\nInclusion of the PARPi veliparib with combination che-\nmotherapy followed by veliparib maintenance therapy\ncannot be recommended at this time. There are no data\nthat this approach is superior, equal, or less toxic than\na switch maintenance (Type: evidence based; beneﬁts/\nharms ratio unknown; Evidence quality: intermediate;\nStrength of recommendation: strong).\nNote: As of this writing, veliparib is not commercially available.\nLiterature review and analysis.\nThe efﬁcacy of PARPi as\nfront-line maintenance therapy has been demonstrated in\nfour randomized trials identiﬁed by the systematic review:\nSOLO1,20 PRIMA,13 PAOLA-1,24 and VELIA.10 Maintenance\ntherapy with PARPi achieved substantial PFS beneﬁt\namong patients with platinum-sensitive, recurrent ovarian\ncancer after a CR/PR to the most recent regimen. SOLO120", "section": "Women with newly diagnosed stage III-IV EOC whose", "page_from": 18, "page_to": 18, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "14c4a4e14db60017d39584e50115f1d6f25203ccb375d18f4b37f8e89511118d"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000074", "text": "therapy with PARPi achieved substantial PFS beneﬁt\namong patients with platinum-sensitive, recurrent ovarian\ncancer after a CR/PR to the most recent regimen. SOLO120\ndemonstrated that, after a CR/PR to ﬁrst-line platinum-\nbased\nchemotherapy,\nolaparib\nmaintenance\ntherapy\nconfers PFS beneﬁts to patients with advanced primary\nBRCA1/2-mutated ovarian cancer (Table 2). The PRIMA\ntrial,13 in which patients newly diagnosed with advanced\novarian cancer were enrolled regardless of their BRCA\nstatus, found a signiﬁcant improvement in PFS compared\nwith placebo in the overall population (Table 2). The PFS\nbeneﬁt was even more pronounced in the HRD-positive\npatient subgroup. Notably, maintenance with niraparib also\ndemonstrated a signiﬁcant reduction in the risk of disease\nprogression or death in the HRD-negative subgroup.\nTwo trials were identiﬁed that considered PARPi combi-\nnation therapy. The PAOLA-1 trial24 investigated the efﬁ-\ncacy of maintenance therapy with a PARPi in patients with\nadvanced ovarian cancer regardless of BRCA mutation\nstatus who are receiving ﬁrst-line standard-of-care treat-\nment including bevacizumab. Results demonstrate ola-", "section": "Women with newly diagnosed stage III-IV EOC whose", "page_from": 18, "page_to": 18, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "921e2ec697fd91da11b85d2ddcfea3aab506328ce354a975fa8f0418d6085cfc"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000075", "text": "advanced ovarian cancer regardless of BRCA mutation\nstatus who are receiving ﬁrst-line standard-of-care treat-\nment including bevacizumab. Results demonstrate ola-\nparib added to bevacizumab maintenance treatment\nsigniﬁcantly improved PFS in the overall population. The\nbeneﬁt was even more pronounced in the BRCA-mutated\nand HRD-positive subgroups. No statistically signiﬁcant\nbeneﬁt was seen in patients with HRD-negative tumors\n(HR, 1.00; 95% CI, 0.75 to 1.35). VELIA10 evaluated\na PARPi, veliparib, in combination with chemotherapy\n(carboplatin and paclitaxel), followed by PARPi mainte-\nnance treatment in the ﬁrst-line setting. The primary\nanalysis demonstrated a signiﬁcantly extended PFS in all\nwomen, regardless of biomarker status. However, it re-\nmains unclear if the addition of veliparib is necessary for the\noverall beneﬁt, because no chemotherapy-plus-placebo\ncomparator arm was included in the study design.\nClinical interpretation. All trials reported to date present\nresults for women who were PARPi na¨ıve at the time of\ninitiation of PARPi therapy. The rapid progression of studies\nexamining PARPi for therapy of recurrent disease to", "section": "Women with newly diagnosed stage III-IV EOC whose", "page_from": 18, "page_to": 18, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "10fa3c7e1e58b1951c4620dd7fbe3b980e7fb6c6b74fa30d3e3c2b3af2d50033"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000076", "text": "results for women who were PARPi na¨ıve at the time of\ninitiation of PARPi therapy. The rapid progression of studies\nexamining PARPi for therapy of recurrent disease to\nsecond-line maintenance to front-line maintenance limited\nhaving a re-exposure scenario. This is an important area of\nunmet need for investigation. Retreatment off study is\nstrongly discouraged because it is unsupported by data and\nprevents the capture of data that may be useful to the\ncommunity. The lack of OS beneﬁt from any of the treat-\nment or maintenance studies to date should be balanced\nagainst factors such as the unknown short-term and late\nrisks (eg, acute myeloid leukemia [AML]/myelodysplastic\nsyndromes [MDS]) and development of collateral re-\nsistance to other agents (eg, platinum).\nPhysicians and patients are strongly encouraged to con-\nsider the full life cycle of advanced ovarian cancer against\ncurrent data in determining when to use PARPi for indi-\nvidual care (Fig 1). The evolution of knowledge regarding\nmechanisms of resistance to PARPi makes clear that pa-\nrameters deﬁning resistance (eg, minimum treatment-free\ninterval, biomarker selection) may need to be taken into", "section": "Women with newly diagnosed stage III-IV EOC whose", "page_from": 18, "page_to": 18, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "5b363fda4f7cbd28ce2d26ae09da9391aa472512c84b50f9550bae4d8ebe7f7a"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000077", "text": "mechanisms of resistance to PARPi makes clear that pa-\nrameters deﬁning resistance (eg, minimum treatment-free\ninterval, biomarker selection) may need to be taken into\naccount in clinical testing of PARPi retreatment. This\nshould be done in the context of well-deﬁned clinical trials.\nThe recommendations herein are focused on the use of\nPARPi for women with ovarian cancer who have not re-\nceived prior treatment with a PARPi.\nData are strong from all studies indicating that women with\ngBRCAm (or the rare sBRCAm) have improved PFS with\nPARPi maintenance therapy with either olaparib or nir-\naparib. The recently published ASCO guideline on germline\nand somatic tumor testing in epithelial ovarian cancer30\nJournal of Clinical Oncology\n3485\nPARP Inhibitors in Ovarian Cancer\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158\nCopyright © 2025 American Society of Clinical Oncology. All rights reserved.", "section": "Women with newly diagnosed stage III-IV EOC whose", "page_from": 18, "page_to": 18, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "f6526d3040c7264aa412e9c16f5ee04cc62578a25716ff0e92b1783e78ee5c68"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000078", "text": "recommends early germline testing. This recommenda-\ntion recognizes that the identiﬁcation of a deleterious\ngermline or somatic mutation in BRCA1 or BRCA2 would\ninform\nPARPi\ntreatment\ndecisions\nfor\nwomen\nwith\nnewly diagnosed disease. The PRIMA study demonstrates\nprogression-free beneﬁt for all women with high-grade\nserous or endometrioid ovarian cancer. Together, these\nresults support consideration of primary maintenance\ntherapy for all women with high-grade serous or endo-\nmetrioid disease. However, no OS results are available from\nthese studies nor data to address conservation of platinum-\nsensitivity in women whose disease progressed while they\nreceived PARPi maintenance or after completion of PARPi\nmaintenance. Those results should inform future treatment\ndecision-making. Given the expectation that early treat-\nment may confer the best outcome, maintenance therapy\nwith PARPi should be offered, with these caveats.\nDoses recommended are the standard dose used for either\nmaintenance or treatment of existing disease and are\nshown in Recommendation 2.0 with a qualiﬁcation in the\ndiscussion for Recommendation 5.2. Eligibility for main-", "section": "PARPi", "page_from": 19, "page_to": 19, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "2e3adf216721d604628f6c9772d528cbd4c2ebfe2644e0a31144fdf9401e853a"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000079", "text": "maintenance or treatment of existing disease and are\nshown in Recommendation 2.0 with a qualiﬁcation in the\ndiscussion for Recommendation 5.2. Eligibility for main-\ntenance therapy includes women with CR/PR to initial\nplatinum-based therapy, to continue for up to 2 years\n(olaparib) or 3 years (niraparib) in women with CRs who are\ntolerating the drug. Longer treatment duration can be\nconsidered for women initiating maintenance therapy with\na PR to platinum-based therapy and demonstrating clinical\nimprovement with PARPi treatment. The patient and her\nphysician should consider risk-beneﬁt balance for pro-\nlonged therapy. Switching PARPis to address tolerance is\nacceptable; however, it is not acceptable to switch to\na different PARPi at the time of disease progression while\nbeing treated with a PARPi.\nInclusion of bevacizumab with primary chemotherapy and\nas maintenance has been evaluated for women with ad-\nvanced stage III-IV, newly diagnosed EOC.31 It is recognized\nthat not all women with newly diagnosed EOC may have\nresults of a germline test at the initiation or even during\nprimary chemotherapy and may have been initiated on\na bevacizumab-containing therapy. Moving to a PARPi", "section": "PARPi", "page_from": 19, "page_to": 19, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "5b838f691f583d50eba96bf889be1bf74b7c835d4442165c041e1d6a3dfc2419"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000080", "text": "results of a germline test at the initiation or even during\nprimary chemotherapy and may have been initiated on\na bevacizumab-containing therapy. Moving to a PARPi\nmaintenance per the FDA approval would then be difﬁcult.\nThe PAOLA-1 trial examined the role of olaparib mainte-\nnance added on top of a regimen including bevacizumab\nwith primary chemotherapy and as maintenance. This\nphase III trial demonstrated beneﬁt with addition of olaparib\nfor women with g/sBRCA and women with HRD score $ 42;\nthere was a 0.9-month difference for women with wild-type\ndisease and no evidence of HRD.24 Thus, addition of\na PARPi in the setting of a bevacizumab combination\nprimary therapy is a reasonable option for those women\nwho have attained a CR/PR to primary therapy. This rec-\nommendation is of moderate strength, because the added\nvalue for women with wild-type disease is questionable and\nmay be informed further by the outcome of the ongoing\nFDA review.\nOnly the VELIA study included a PARPi with chemotherapy\nin initial treatment of ovarian cancer.10 Inclusion of veliparib\nwith chemotherapy and continued into maintenance\ntherapy for 30 cycles may be offered if veliparib becomes", "section": "PARPi", "page_from": 19, "page_to": 19, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "3c1fb675fc2d8b797cae9f815314f099de4343e0edca82207be981dbc6dc5f79"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000081", "text": "in initial treatment of ovarian cancer.10 Inclusion of veliparib\nwith chemotherapy and continued into maintenance\ntherapy for 30 cycles may be offered if veliparib becomes\ncommercially available.10 There are no data, to our\nknowledge, to demonstrate inclusion during chemotherapy\nfollowed by maintenance provides equal to or greater\nbeneﬁt, or reduced toxicity, compared with switch main-\ntenance approaches. Furthermore, long-term safety data\nfor inclusion of veliparib with chemotherapy followed by\nmaintenance are needed, especially to address risk of AML/\nMDS. Substitution of another PARPi in the VELIA regimen is\nstrongly discouraged, because safety, dose, and duration of\nniraparib and rucaparib have not been deﬁned. Use of\nolaparib requires a carboplatin dose modiﬁcation and at-\ntenuation of the olaparib exposure per cycle.32-34 There are\nalso limited long-term safety data for the olaparib/carbo-\nplatin/paclitaxel regimen.34\nCLINICAL QUESTION 3\nRecurrent Ovarian Cancer: Second-Line or Greater\nMaintenance and Treatment\nIs PARPi monotherapy recommended for recurrent EOC?\nIf so:\na. In which settings (eg, second-line maintenance or\ntreatment of recurrent disease)?", "section": "PARPi", "page_from": 19, "page_to": 19, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "eb6c9c4927d91289d5bf6fc81a7a6e89b3f2febe62971a582406f86f4948b78c"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000082", "text": "Maintenance and Treatment\nIs PARPi monotherapy recommended for recurrent EOC?\nIf so:\na. In which settings (eg, second-line maintenance or\ntreatment of recurrent disease)?\nb. At what dose and duration?\nRecommendation 3.0\nPARPi monotherapy maintenance (second-line or more)\nmay be offered to patients with EOC who have not already\nreceived a PARPi and who have responded to platinum-\nbased therapy regardless of BRCA mutation status; treat-\nment is continued until progression of disease or toxicity\ndespite dose reductions and best supportive care.\n• Options include: olaparib 300 mg every 12 hours;\nrucaparib 600 mg every 12 hours; niraparib 200-\n300 mg once daily.\n(Type: evidence based, beneﬁts outweigh harms; Evidence\nquality: high; Strength of recommendation: strong)\nRecommendation 3.1\nTreatment with a PARPi should be offered to patients with\nrecurrent EOC who have not already received a PARPi and\nhave a germline or somatic pathogenic or likely pathogenic\nvariants in BRCA1 or BRCA2 genes.\n• Options include: olaparib 300 mg every 12 hours;\nrucaparib 600 mg every 12 hours; niraparib 200-\n300 mg once daily.\n(Type: evidence based, beneﬁts outweigh harms; Evidence", "section": "PARPi", "page_from": 19, "page_to": 19, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "a8945782dd522c9fc4d63765be3e57c0d524dbe8187ab06c80e49897de41a58d"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000083", "text": "• Options include: olaparib 300 mg every 12 hours;\nrucaparib 600 mg every 12 hours; niraparib 200-\n300 mg once daily.\n(Type: evidence based, beneﬁts outweigh harms; Evidence\nquality: high; Strength of recommendation: strong)\nRecommendation 3.2\nTreatment with a PARPi monotherapy should be offered to\npatients with recurrent EOC who have not already received\n3486 © 2020 by American Society of Clinical Oncology\nVolume 38, Issue 30\nTew et al\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158\nCopyright © 2025 American Society of Clinical Oncology. All rights reserved.", "section": "PARPi", "page_from": 19, "page_to": 19, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "af1b8c88ef1775e94c233234b4bf4ec2ae38593f3fcbeb46836128c1e0ac3791"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000084", "text": "a PARPi and whose tumor demonstrates genomic in-\nstability, as determined by Myriad myChoice CDx, and has\nnot recurred within 6 months of platinum-based therapy\n(Type: evidence based, beneﬁts outweigh harms; Evidence\nquality: high; Strength of recommendation: strong).\nRecommendation 3.3\nPARPis are not recommended for treatment of BRCAwt or\nplatinum-resistant, recurrent EOC (Type: evidence based,\nbeneﬁts outweigh harms; Evidence quality: high; Strength\nof recommendation: strong).\nLiterature review and analysis.\nThe systematic review\nidentiﬁed 13 trials in total, nine of which were open label,\nphase II studies12,14-16,18,21,22,25,26 and four of which were\nphase II or III controlled trials.11,17,19,23 In maintenance\ntherapy for the second-line or greater setting, Study 19,17,28\nSOLO2,23 NOVA,19 and ARIEL311 all demonstrated signif-\nicant efﬁcacy of PARPis compared with placebo (Table 3).\nFor recurrent disease, Study 42,14 SOLO3,22 Study 1016,\nARIEL2,25 and QUADRA21 all reported a signiﬁcant im-\nprovement in response and PFS in patients with BRCA\nmutations (Table 4).\nClinical interpretation:\n• Maintenance: Four trials investigated the efﬁcacy of", "section": "PARPi", "page_from": 20, "page_to": 20, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "83e5ab2dd9790d69ab06961a33d33cc4962856d552026983dd4048c23b041182"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000085", "text": "provement in response and PFS in patients with BRCA\nmutations (Table 4).\nClinical interpretation:\n• Maintenance: Four trials investigated the efﬁcacy of\nPARPi maintenance therapy in platinum-sensitive\nrecurrent disease, and all showed an improvement\nin PFS.11,17,19,23 Across all studies, women with\na g/sBRCA mutation had the most robust clinical\nimprovements. OS results just reported on the SOLO2\ntrial, which investigated olaparib monotherapy in pa-\ntients with platinum-sensitive, recurrent, g/sBRCA1/\n2m EOC who had received $ 2 lines of chemotherapy.\nThe preplanned, ﬁnal, OS analysis with data maturity of\n61% demonstrated that olaparib extended OS by\napproximately 13 months compared with placebo\n(38.8 v 51.7 months; HR, 0.74, 95% CI, 0.54 to 1.00;\nP 5 .054) in the full analysis set and extended OS by\n15 months with olaparib compared with placebo\n(37.4 v 52.4 months; HR, 0.71; 95% CI, 0.52 to 0.97;\nP 5 .031) in the prespeciﬁed sensitivity analysis of\npatients with germline BRCA mutation.\n• Recurrent disease: The ﬁrst approval for PARPis was\nfor use in the treatment setting for recurrent ovarian\ncancer for PARPi-na¨ıve women. Olaparib is FDA approved", "section": "PARPi", "page_from": 20, "page_to": 20, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "53e569605aa3f1028a41e794878363faab8d4e70e894750eafa114ffc7ef3d93"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000086", "text": "• Recurrent disease: The ﬁrst approval for PARPis was\nfor use in the treatment setting for recurrent ovarian\ncancer for PARPi-na¨ıve women. Olaparib is FDA approved\nfor the treatment of patients with gBRCAm ovarian, fal-\nlopian, or primary peritoneal cancer who have received\n$ 3 prior lines of chemotherapy. Rucaparib is approved\nfor the treatment of patients with gBRCAm–associated\novarian, fallopian tube, or primary peritoneal cancer who\nhave been treated with $ 2 chemotherapy regimens.\nRucaparib yielded beneﬁt in ARIEL2 in a small cohort (n 5\n5) of ovarian cancers with RAD51C or RAD51D mutations,\nwith three PRs and two patients with prolonged stable\ndisease for 8.3 and 11.0 months.25\nThe recently reported, single-arm QUADRA trial of nir-\naparib treatment in recurrent ovarian cancer met its pri-\nmary end point demonstrating activity in fourth- and\nﬁfth-line treatment of patients with gBRCA and positive\nfor HRD who were PARPi na¨ıve and platinum sensitive to\ntheir last platinum therapy (n 5 47). The study had an\nORR of 28% and a median duration of response of 9.2\nmonths. It was approved in 2019 for patients with ad-\nvanced ovarian, fallopian tube, or primary peritoneal", "section": "PARPi", "page_from": 20, "page_to": 20, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "f08adf78186f77c19116ed649aed3c0ecabd6ee4bf408e043de685b0bc5f1307"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000087", "text": "ORR of 28% and a median duration of response of 9.2\nmonths. It was approved in 2019 for patients with ad-\nvanced ovarian, fallopian tube, or primary peritoneal\ncancer treated with $ 3 prior chemotherapy regimens\nwho are PARPi na¨ıve and whose cancer is associated\nwith HRD-positive status determined using the myChoice\nCDx as either tumor BRCA mutated and/or with a ge-\nnomic instability score $ 42. Patients with HRD-positive\ncancers but without BRCA mutations must have expe-\nrienced progression at least 6 months after the last dose\nof platinum-based therapy (ie, must have platinum-\nsensitive disease).\nDosing recommendations for treatment with all three\nagents are the same as deﬁned previously for use in\nmaintenance therapy. PARPi treatment is not generally\nrecommended for treatment of platinum-resistant cancer. It\nhas , 5% activity for treatment of BRCAwt, platinum-\nresistant, recurrent EOC. Any use of PARPi in the\nplatinum-resistant setting is recommended to occur in the\nsetting of a clinical trial, whether as a single agent or in\nchemotherapy, antiangiogenesis, or immunotherapy com-\nbinations. Nor should PARPis be readministered after", "section": "PARPi", "page_from": 20, "page_to": 20, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "0044b5cb842331b79e1cbb1e0d79638c803b3394f0dbd2f8429a704bc74dcb29"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000088", "text": "setting of a clinical trial, whether as a single agent or in\nchemotherapy, antiangiogenesis, or immunotherapy com-\nbinations. Nor should PARPis be readministered after\nprior exposure and progression on PARPi therapy, because\nthere are no data to support that re-exposure in this setting\nis beneﬁcial, and agent approval does not specify this\noption. Clinical trial participation is encouraged.\nCLINICAL QUESTION 4\nPARPi in Combination\nAre there settings where a PARPi in combination with\nchemotherapy or other targeted therapy are recommended?\nRecommendation 4.0\nPARPis are not recommended for use in combination with\nchemotherapy, other targeted agents, or immune-oncology\nagents outside the context of a clinical trial. Clinical trial\nparticipation is encouraged (Type: informal consensus,\nbeneﬁts outweigh harms; Evidence quality: insufﬁcient;\nStrength of recommendation: moderate).\nClinical interpretation.\nThere are limited data and nu-\nmerous clinical trials now investigating the roles of PARPis\nin combination with chemotherapy, antiangiogenesis, or\nimmunotherapies as treatment and in maintenance. The\naddition of PARPi is safe given no signiﬁcant overlapping", "section": "PARPi", "page_from": 20, "page_to": 20, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "f01f24799cfeb1586f7a69c63701a136e881d4f6ae734d18e12353409145ea74"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000089", "text": "in combination with chemotherapy, antiangiogenesis, or\nimmunotherapies as treatment and in maintenance. The\naddition of PARPi is safe given no signiﬁcant overlapping\ntoxicity for women receiving hormonal blockade (ie, aro-\nmatase inhibitor) for synchronous breast cancer. However,\nthere are no outcome data speciﬁc to this approach, to our\nknowledge. There is an increasing need to understand\nwhen and how to retreat with a PARPi, especially when\nJournal of Clinical Oncology\n3487\nPARP Inhibitors in Ovarian Cancer\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158\nCopyright © 2025 American Society of Clinical Oncology. All rights reserved.", "section": "PARPi", "page_from": 20, "page_to": 20, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "febb561f55d879041b3b45152caf7548d62f3221839c1fac7cd53fdb16169c0a"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000090", "text": "there has been progression while receiving a prior PARPi.\nThese unmet needs can only be clariﬁed with well-designed\nrandomized trials stratiﬁed for confounding elements such\nas g/sBRCA status, prior exposure to platinum agents, prior\nexposure to a PARPi, and accounting for AE risks. At this\ntime, it is not recommended to re-treat with PARPi, even for\npatients with g/sBRCA platinum-sensitive disease, nor to\nuse combination therapy not in a clinical trial.\nCLINICAL QUESTION 5\nAdverse Events\nHow should clinicians manage the speciﬁc toxicities of the\nvarious PARPis?\nRecommendation 5.0 Anemia\na. Patients requiring a blood transfusion for symptom\nrelief and/or hemoglobin level , 8 g/dL should be\nmonitored. PARPi dose should be reduced with evi-\ndence of repeated anemia to avoid multiple transfusions.\nb. Patients with progressive anemia may be offered\ngrowth factor per ASCO guidelines and physician and\npatient comfort.\n(Type: informal consensus, beneﬁts outweigh harms; Evi-\ndence quality: insufﬁcient; Strength of recommendation:\nmoderate).\nRecommendation 5.1 Neutropenia\na. Growth factor is not indicated for use in patients re-\nceiving daily PARPi.", "section": "PARPi", "page_from": 21, "page_to": 21, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "5cfb877da141cbda1a6b8ccccf9cd32513d6b780f1b26210f218b0dee2d39b72"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000091", "text": "dence quality: insufﬁcient; Strength of recommendation:\nmoderate).\nRecommendation 5.1 Neutropenia\na. Growth factor is not indicated for use in patients re-\nceiving daily PARPi.\nb. Neutropenia (grade 4 lasting $ 5-7 days or associated\nwith fever) should result in dose hold until recovery of\ninfection and granulocyte count, then dose may be\nreduced. Growth factor support may be used in this\nsetting to support patient safety during the drug hold.\n(Type: informal consensus, beneﬁts outweigh harms; Evi-\ndence quality: insufﬁcient; Strength of recommendation:\nmoderate),\nRecommendation 5.2 Platelets\na. Thrombocytopenia is most common with nir-\naparib. Niraparib dosing guidelines should be used to\nlower starting dose (200 mg) based on weight and\nplatelet count.\nb. Discontinue PARPi for persistent thrombocytopenia or\nsigniﬁcant bleeding despite dose reduction.\n(Type: informal consensus, beneﬁts outweigh harms; Evi-\ndence quality: insufﬁcient; Strength of recommendation:\nmoderate).\nRecommendation 5.3 Persistent cytopenia\na. Evaluation for treatment-related MDS/AML should be\ninitiated in patients with persistent cytopenia that\noccurs despite drug hold.", "section": "PARPi", "page_from": 21, "page_to": 21, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "a28a3b4a24d958177a99484e426ad425142d56b50c72c3ee3bedaf64ee1d0722"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000092", "text": "moderate).\nRecommendation 5.3 Persistent cytopenia\na. Evaluation for treatment-related MDS/AML should be\ninitiated in patients with persistent cytopenia that\noccurs despite drug hold.\n(Type: informal consensus, beneﬁts outweigh harms; Evi-\ndence quality: insufﬁcient; Strength of recommendation:\nmoderate).\nRecommendation 5.4 Nausea\na. Many patients will have tachyphylaxis of nausea\nsymptoms over the ﬁrst cycle of therapy.\nb. Persistent\nnausea\nrequiring\ndaily\nantiemetic\nin-\ntervention, causing a reduction in performance status,\nand/or resulting in . 5% weight loss should result in\ndose reduction.\n(Type: informal consensus, beneﬁts outweigh harms; Evi-\ndence quality: insufﬁcient; Strength of recommendation:\nmoderate).\nClinical interpretation.\nPARPis, while generally well tol-\nerated, have class- and agent-speciﬁc AEs, some of which\nmay lead to requirements for dose modiﬁcation (Table 6).\nThe most common of those include fatigue, anemia,\nneutropenia, thrombocytopenia, persistent cytopenias, and\nnausea. Other, less common, class-effect AEs include\nvomiting and diarrhea, headache, elevation in levels of liver\nfunction enzymes or creatinine, and the rarer, but also more", "section": "PARPi", "page_from": 21, "page_to": 21, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "d2402d625832c9e9d7e67cb345fa2395c15c4972d0812aa664a5a1284ee935b3"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000093", "text": "nausea. Other, less common, class-effect AEs include\nvomiting and diarrhea, headache, elevation in levels of liver\nfunction enzymes or creatinine, and the rarer, but also more\nserious, pneumonitis and leukemia risks. Fatigue maybe\nmultifactorial, due to and/or representing cytopenias, stress\nof nausea, and other elements, and may also be a conse-\nquence of persistent grade 1 and/or grade 2 events. Thus,\nbecause these are daily, continuously administered agents,\nspecial attention should be paid to low-grade AEs, and any\ngrade 2 AE requiring a dose hold should be accompanied\nTABLE 6. Dose Modiﬁcation for PARPi\nPARPi\nStarting\nDose\nInitial Dose\nReduction\nSecond Dose\nReduction\nThird Dose\nReduction\nFinal\nReduction\nOlaparib\n300 mg every\n12 hours\n200 mga every\n12 hours\n150 mga every\n12 hours\nDiscontinue\n–\nRucaparib\n600 mg every\n12 hours\n500 mg every\n12 hours\n400 mg every\n12 hours\n300 mg every\n12 hours\nDiscontinue\nNiraparib\n300 mg once\ndaily\n200 mg once\ndaily\n100 mg once daily\nDiscontinue\n–\nNiraparib if weight , 77 kg and/or platelet counts\n, 150,000/mL (UK based on weight , 58 kg)\n200 mg once\ndaily\n100 mg once\ndaily\nDiscontinue\n–\n–", "section": "PARPi", "page_from": 21, "page_to": 21, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "66e48c152a0489e5b7d2d4908834f5b43fafd8c1e3de284879ce22e666ea77c6"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000094", "text": "200 mg once\ndaily\n100 mg once daily\nDiscontinue\n–\nNiraparib if weight , 77 kg and/or platelet counts\n, 150,000/mL (UK based on weight , 58 kg)\n200 mg once\ndaily\n100 mg once\ndaily\nDiscontinue\n–\n–\nAbbreviations: –, not applicable; PARPi, PARP inhibitor; UK, United Kingdom.\naDose reductions are based on general practice standard and deviate slightly from AstraZeneca’s Prescribing Information\n3488 © 2020 by American Society of Clinical Oncology\nVolume 38, Issue 30\nTew et al\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158\nCopyright © 2025 American Society of Clinical Oncology. All rights reserved.", "section": "PARPi", "page_from": 21, "page_to": 21, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "bff9d665bcfdecc1bf742961a58182f433d29c63a2c599f86034daff428585f7"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000095", "text": "by a dose reduction to minimize risk of a second dose hold\nand further or persistent events or injury. Re-escalation or\nresumption of initial dose is never recommended.\nAnemia. Anemia is found across all PARPi use and is\ncharacterized by a macrocytic phenotype with mean cor-\npuscular volumes that can reach . 105 (units) but is not\na vitamin B12–dependent pernicious anemia functionally.\nThe anemia may present early or slowly progressively; have\nthe commonly associated effects of fatigue, decreased\nexercise tolerance, and shortness of breath; and come on at\ndifferent levels of anemia across patients depending on\ntheir underlying tolerance. Interventions include drug hold,\ndose reduction, transfusion, and consideration of growth\nfactor support. The latter is recommended to follow existing\nASCO guidelines and appears to be used less commonly.\nAmple experience demonstrates that drug holding without\nassociated other change will result in recurrence of the\nanemia upon reinstitution of the agent. Thus, dose modi-\nﬁcation with or without transfusion to acutely ameliorate\neffects of anemia is recommended.\nNeutropenia. More variable across agents is the presence", "section": "PARPi", "page_from": 22, "page_to": 22, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "6a775ab8e15bd242385295f216593d277c33a19e74baf678329b03f8a1e0c2c9"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000096", "text": "ﬁcation with or without transfusion to acutely ameliorate\neffects of anemia is recommended.\nNeutropenia. More variable across agents is the presence\nand depth of neutropenia. All PARPis have the potential for\ntrilineage suppression; however, the severity of neutropenia\nappears to vary across agents and patients. The degree of\nprior marrow suppressive treatment(s) and bone marrow\nreserve may also contribute to the tolerance of PARPi by the\nbone marrow. The degree of myelosuppression has not\nbeen shown to reach the levels deﬁned in the ASCO 2015\nGuideline Update for prophylactic use of growth factor\nsupport recommended for use with a . 20% risk of\nneutropenia with fever.35 Thus, growth factor support is not\nrecommended for prophylactic use during PARPi therapy.\nThe 2015 guidelines also reinforce that growth factors\nshould be administered 24-72 hours after completion of the\nchemotherapy, making consistent use of such agents not\nfeasible when administering a daily treatment regimen such\nas a PARPi. Grade 4 neutropenia of $ 5-7 days or grade 3\nwith fever are indications for holding PARPi. Severe cir-\ncumstances warrant consideration of short-acting growth", "section": "PARPi", "page_from": 22, "page_to": 22, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "8801b90372d0c1b57ff03da845fcc7aaac4190417085f69a25898f8d7b8da369"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000097", "text": "as a PARPi. Grade 4 neutropenia of $ 5-7 days or grade 3\nwith fever are indications for holding PARPi. Severe cir-\ncumstances warrant consideration of short-acting growth\nfactor support, such as 3 days of neupogen, to mitigate\nfurther decline. If that is done, PARPi should not be\nrestarted until resolution of fever, a granulocyte count of\n$ 1,000/dL, and adequate time (ie, 48-72 hours) have\nelapsed since the last dose of growth factor.\nThrombocytopenia. Thrombocytopenia has been reported\nwith all commercially available PARPis, with variability in\nfrequency and depth across agents. Of the three approved\nPARPis for ovarian cancer, niraparib had the greatest\nimpact on platelet counts, and the risk of thrombocytopenia\nwas greatest with initial exposures. Recommendations have\nbeen proposed in the United States (pending FDA ap-\nproval) and the United Kingdom (recommended in drug\ninsert) to modify doses as a function of age and/or weight.\nUnited Kingdom recommendations are based on the\nﬁnding from the NOVA trial that there was a greater pro-\nportion grade 3/4 adverse reactions including thrombo-\ncytopenia in women in the lowest quartile of weight (# 58", "section": "PARPi", "page_from": 22, "page_to": 22, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "d4427923b0c327e22152be789f16fa768a363ed9f67acb00ac292717b0be6f5d"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000098", "text": "ﬁnding from the NOVA trial that there was a greater pro-\nportion grade 3/4 adverse reactions including thrombo-\ncytopenia in women in the lowest quartile of weight (# 58\nkg) and state that a starting dose of 200 mg is recom-\nmended for women weighing , 58 kg.19 Pending US\ndosing recommendations indicate that 200 mg be the\nstarting dose for women weighing , 77 kg and/or with\na starting platelet count , 150,000/mL. Dose hold followed\nby reduction is the recommended approach to grade 3/4\nthrombocytopenia to avoid the requirement for platelet\ntransfusions. Patients who develop persistent or recurrent\nthrombocytopenia while receiving a reduced dose or dose\nhold of PARPi should be evaluated per the following section\non persistent cytopenias.\nPersistent cytopenia, AML, MDS.\nAs with all DNA-\ndamaging agents, there is a risk for inducing injury, with\nthe bone marrow the most common site for such injury. It is\nunclear the extent to which the PARPis contribute to un-\nderlying injury that may have occurred from prior exposures\nsuch as platinums, topoisomerase 1 and 2 inhibitors, and\nantimetabolites, all of which have some reported risks. In", "section": "PARPi", "page_from": 22, "page_to": 22, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "2d94fcc9f40dfe4697f928a7e8ff0f6f178b7e3c6ff8c29e4f9f53af2dda0079"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000099", "text": "derlying injury that may have occurred from prior exposures\nsuch as platinums, topoisomerase 1 and 2 inhibitors, and\nantimetabolites, all of which have some reported risks. In\naddition, women are living longer and thus having more\noverall treatment exposures, which may contribute to ac-\ncumulated injury. The most common ﬁrst sign is devel-\nopment of a single or multiple persistent cytopenias. Such\na ﬁnding should trigger drug discontinuation and evaluation\nfor common underlying causes, such as evaluation of iron\nstores, vitamin B12 level, and folate status, in the case of\npersistent anemia. A low threshold should be used for\nmoving to bone marrow evaluation to rule out development\nof MDS or AML, especially with persistent multilinear\ncytopenia. Where appropriate, early hematology consul-\ntation is recommended.\nNausea. Nausea occurs in various frequency and severity\nacross patients and PARPis. Many patients will have\ntachyphylaxis of nausea symptoms during the ﬁrst cycle of\ntherapy, often without institution of antiemetic therapy or\ndose reduction. Some patients may ﬁnd a light meal or\nsnack before taking a PARPi improves their symptoms.", "section": "PARPi", "page_from": 22, "page_to": 22, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "13b7f9e0b85d3e55ce5fe71f9bfba9cc41f7779128cabf6dd3c713f397512d36"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000100", "text": "therapy, often without institution of antiemetic therapy or\ndose reduction. Some patients may ﬁnd a light meal or\nsnack before taking a PARPi improves their symptoms.\nPersistent nausea associated with vomiting, weight loss\n. 5%, and/or reduction in performance status should be\nevaluated to rule out other causes, such as bowel ob-\nstruction. Absent other causes, any situation with a re-\nquirement for daily antiemetic intervention, causing\na reduction in performance status, and/or resulting in\n. 5% weight loss should result in dose hold and then dose\nreduction upon improvement and reinstitution.\nPATIENT AND CLINICIAN COMMUNICATION\nWomen with advanced ovarian cancer considering treat-\nment or maintenance with a PARPi do so during a time of\nrapidly emerging new data and complex regulatory ap-\nprovals. It is important to recognize that patients no longer\nrely solely on their medical team for information and often\naccess other sources online, in print, or through social\nJournal of Clinical Oncology\n3489\nPARP Inhibitors in Ovarian Cancer\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158", "section": "PARPi", "page_from": 22, "page_to": 22, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "2e149c3a31344b5164cd149668df9036a1094ac533670576e310765c3c09ab7c"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000101", "text": "Journal of Clinical Oncology\n3489\nPARP Inhibitors in Ovarian Cancer\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158\nCopyright © 2025 American Society of Clinical Oncology. All rights reserved.", "section": "PARPi", "page_from": 22, "page_to": 22, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "c985f11d4444a6cdf0ce1d365a201170a8cf12e11ea5332f336eb0f360ff8a94"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000102", "text": "media and support groups. Shared decision-making is\nessential, and patients should be informed that the\nevidence-based options for treatment (or maintenance), as\nwell as the potential beneﬁts and risks communicated by\nthe physician, are based on knowledge that continues to\nevolve. Consideration of the patient’s preferences should be\nsupported in deciding the best course of treatment.\nFor patients faced with a decision to undergo potentially\nyears of treatment or maintenance with a PARPi, it is es-\nsential that providers thoroughly explain the potential im-\npact on QoL during the initial 30- to 60-day adjustment\nperiod and provide a plan for aggressive management of\nAEs during this phase and beyond. Patients should also be\ninformed that a potential dose reduction may be reasonable\nto manage AEs. Connection with other patients who have\nalready navigated adjustment to PARPis, through local or\non-line support networks, may increase tolerability and\nadherence.\nFor recommendations and strategies to optimize patient-\nclinician communication, see “Patient-Clinician Commu-\nnication: American Society of Clinical Oncology Consensus\nGuideline.”36\nHEALTH DISPARITIES", "section": "PARPi", "page_from": 23, "page_to": 23, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "0166f5d48481d4a0760a2e841a32121f03dfef799da2d0a8e1ce15eb2f96ed28"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000103", "text": "clinician communication, see “Patient-Clinician Commu-\nnication: American Society of Clinical Oncology Consensus\nGuideline.”36\nHEALTH DISPARITIES\nAlthough ASCO clinical practice guidelines represent ex-\npert recommendations on the best practices in disease\nmanagement to provide the highest level of cancer care, it is\nimportant to note that many patients have limited access to\nmedical care, and access to drugs can vary between\ncountries. Racial and ethnic disparities in health care\ncontribute signiﬁcantly to this problem in the United States.\nA recent, large, population-based study of multigene testing\nin patients with breast or ovarian cancer observed racial\ndisparities in genetic testing.37 While approximately 34% of\nWhite women were tested, only about 22% of Black women\nand 24% of Hispanic women received testing. Further-\nmore, racial/ethnic differences in pathogenic variants ob-\nserved in patients with ovarian cancer include BRCA1,\nwhich is reported to be 1% in individuals of African descent,\n7% in Whites and 16% in Hispanics.37 Patients with cancer\nwho are members of racial/ethnic minorities also suffer\ndisproportionately from comorbidities, experience more", "section": "PARPi", "page_from": 23, "page_to": 23, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "afb0b83d814b6a789f8626b958182d1a3b41b59b2d100c6ec0543534a5422303"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000104", "text": "7% in Whites and 16% in Hispanics.37 Patients with cancer\nwho are members of racial/ethnic minorities also suffer\ndisproportionately from comorbidities, experience more\nsubstantial obstacles to receiving care, are more likely to be\nuninsured, and are at greater risk of receiving care of poor\nquality than other Americans.38-41 It is also recognized and\nunfortunate that there are disparities in adherence to\ntreatment guidelines.42 As such, it is important for clinicians\nto offer appropriate testing and to address patients’\nquestions, concerns, and/or misconceptions. Many other\npatients lack access to care because of their geographic\nlocation and distance from appropriate treatment facilities.\nAwareness of these disparities in access to care should be\nconsidered in the context of this clinical practice guideline,\nand health care providers should strive to deliver the highest\nlevel of cancer care to these vulnerable populations.\nMULTIPLE CHRONIC CONDITIONS\nCreating\nevidence-based\nrecommendations\nto\ninform\ntreatment of patients with additional chronic conditions,\na situation in which the patient may have $ 2 such con-\nditions—referred\nto\nas\nmultiple\nchronic\nconditions", "section": "PARPi", "page_from": 23, "page_to": 23, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "75716f6ea3d0156208a59c8feb112fc9c5d4bbc6d1d9ff1c86da9552a426076a"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000105", "text": "recommendations\nto\ninform\ntreatment of patients with additional chronic conditions,\na situation in which the patient may have $ 2 such con-\nditions—referred\nto\nas\nmultiple\nchronic\nconditions\n(MCC)—is challenging. Patients with MCC are a complex\nand heterogeneous population, making it difﬁcult to ac-\ncount for all the possible permutations to develop speciﬁc\nrecommendations for care. In addition, the best available\nevidence for treating index conditions, such as cancer, is\noften from clinical trials whose study selection criteria may\nexclude these patients to avoid potential interaction effects\nor confounding of results associated with MCC. As a result,\nthe reliability of outcome data from these studies may be\nlimited, thereby creating constraints for expert groups to\nmake recommendations for care in this heterogeneous\npatient population.\nBecause many patients for whom guideline recommen-\ndations apply present with MCC, any treatment plan needs\nto take into account the complexity and uncertainty created\nby the presence of MCC and highlights the importance of\nshared decision-making regarding guideline use and\nimplementation. Therefore, in consideration of recom-", "section": "PARPi", "page_from": 23, "page_to": 23, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "a33308ac35da1aac0088762d89e07ddf7cfa6c45ea58ae36bb66b2cb6afaafad"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000106", "text": "by the presence of MCC and highlights the importance of\nshared decision-making regarding guideline use and\nimplementation. Therefore, in consideration of recom-\nmended care for the target index condition, clinicians\nshould review all other chronic conditions present in the\npatient and take those conditions into account when for-\nmulating the treatment and follow-up plan.\nIn light of the aforementioned considerations, practice\nguidelines should provide information on how to apply the\nrecommendations for patients with MCC, perhaps as\na qualifying statement for recommended care. This may\nmean that some or all of the recommended care options are\nmodiﬁed or not applied, as determined by best practice in\nconsideration of any MCC.\nCOST IMPLICATIONS\nIncreasingly, individuals with cancer are required to pay\na larger proportion of their treatment costs through de-\nductibles and coinsurance.43,44 Higher patient out-of-\npocket costs are a barrier to initiating and adhering to\nrecommended cancer treatments.45,46 PARPis are costlier\nthan other available therapies, 18.8, 6.9, and 2.2-2.7 times\ncostlier than paclitaxel, pembrolizumab, and bevacizumab,", "section": "PARPi", "page_from": 23, "page_to": 23, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "95e5751b39cf0cf6de2c139f6d3c9138cc0b0917fd616c29c9b1b93dd5076077"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000107", "text": "recommended cancer treatments.45,46 PARPis are costlier\nthan other available therapies, 18.8, 6.9, and 2.2-2.7 times\ncostlier than paclitaxel, pembrolizumab, and bevacizumab,\nrespectively. Patients’ out-of-pocket costs may vary\ndepending on insurance coverage. Coverage may originate\nin the medical or pharmacy beneﬁt, which may have dif-\nferent cost-sharing arrangements. Patients should be\naware that different products may be preferred or covered\nby their particular insurance plan. Even with the same\ninsurance plan, the price may vary between different\npharmacies. While most insurance carriers will provide\nsome coverage for PARPis, the patient’s copayment can\nremain prohibitive, nonetheless. Medicare, which is used\nby many patients with ovarian cancer, given that the\n3490 © 2020 by American Society of Clinical Oncology\nVolume 38, Issue 30\nTew et al\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158\nCopyright © 2025 American Society of Clinical Oncology. All rights reserved.", "section": "PARPi", "page_from": 23, "page_to": 23, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "e16e8fc451c9b1172e555aa080a79c3c5a17ab828c26cba711d4f56e47d3a9a7"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000108", "text": "disease largely affects older women, does cover most\nPARPis. The amount of coverage and the size of copay,\nhowever, vary from state to state. When discussing ﬁnancial\nissues and concerns, patients should be made aware of any\nﬁnancial counseling services available to address this\ncomplex and heterogeneous landscape.47\nDiscussion of cost can be an important part of shared\ndecision-making.47 Clinicians should discuss with patients\nthe use of less expensive alternatives when it is practical\nand feasible for treatment of the patient’s disease and when\nthere are $ 2 treatment options that are comparable in\nterms of beneﬁts and harms.47\nEXTERNAL REVIEW AND OPEN COMMENT\nThe draft recommendations were released to the public for\nopen comment from February 11, 2020, through February\n25, 2020. Response categories of “Agree as written,”\n“Agree with suggested modiﬁcations,” and “Disagree. See\ncomments” were captured for every proposed recom-\nmendation, with 58 written comments received. A total of\n12 respondents, who had not previously reviewed the\nrecommendations, either agreed or agreed with slight\nmodiﬁcations to the vast majority of the recommendations.", "section": "PARPi", "page_from": 24, "page_to": 24, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "e2d0f1b0a29d705c32709ce4beff8d38611244fd45ac3dad8f90c0b76c60084f"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000109", "text": "12 respondents, who had not previously reviewed the\nrecommendations, either agreed or agreed with slight\nmodiﬁcations to the vast majority of the recommendations.\nExpert Panel members reviewed comments from all\nsources and determined whether to maintain original draft\nrecommendations, revise with minor language changes, or\nconsider major recommendation revisions. All changes\nwere incorporated prior to Clinical Practice Guideline\nCommittee review and approval.\nThe draft was submitted to two external reviewers with\ncontent expertise. It was rated as high quality, and it was\nagreed it would be useful in practice. Speciﬁc comments\nwere reviewed by the Expert Panel and integrated into the\nﬁnal manuscript before submission to JCO.\nGUIDELINE IMPLEMENTATION\nASCO guidelines are developed for implementation across\nhealth settings. Each ASCO guideline includes a member\nfrom ASCO’s Practice Guideline Implementation Network\n(PGIN) on the panel. The additional role of this PGIN rep-\nresentative on the guideline panel is to assess the suitability of\nthe recommendations to implementation in the community\nsetting and also to identify any other barrier to implementation", "section": "PARPi", "page_from": 24, "page_to": 24, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "13546f83e9b483f22b81a589560a56b0fd15e9ba88747e0ed121ec38bf1392cd"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000110", "text": "resentative on the guideline panel is to assess the suitability of\nthe recommendations to implementation in the community\nsetting and also to identify any other barrier to implementation\na reader should be aware of. Barriers to implementation\ninclude the need to increase awareness of the guideline\nrecommendations among front-line practitioners and survi-\nvors of cancer and caregivers, and also to provide adequate\nservices in the face of limited resources. The guideline\nBottom Line box was designed to facilitate implementation of\nrecommendations. This guideline will be distributed widely\nthrough the ASCO PGIN. ASCO guidelines are posted on the\nASCO website and most often published in JCO.\nLIMITATION OF THE RESEARCH AND FUTURE RESEARCH\nA major limitation of these guidelines is their focus on\nwomen who are PARPi na¨ıve. The physician and patient\nneed to consider the full lifetime of the patient and disease\nand weigh the data beneﬁts and risks, especially given the\nlack of an OS beneﬁt to date. A critical unmet need is to\nunderstand the opportunities and where the beneﬁts may\nbe for re-exposure to a PARPi after an initial good response", "section": "PARPi", "page_from": 24, "page_to": 24, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "2c14f8d6eff018171ddffb6713ec89931ad4eafb55508343cc9f37d288a1bcf4"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000111", "text": "lack of an OS beneﬁt to date. A critical unmet need is to\nunderstand the opportunities and where the beneﬁts may\nbe for re-exposure to a PARPi after an initial good response\nand in combinations after a progression outcome. Pre-\nclinical development is moving rapidly and some empirical\nand some data-driven clinical trials have begun. Reuse of\na PARPi should only be considered in such a trial situation\nuntil data develop to guide evidence-based clinical care.\nFuture clinical trials that examine PARPi timing within the\ntreatment life cycle and optimal duration of treatment could\nhelp establish the best risk-beneﬁt balance practice pattern\nfor PARPi use in the management of EOC.\nADDITIONAL RESOURCES\nMore information, including a supplement with additional\nevidence tables, slide sets, and clinical tools and resources,\nis available at www.asco.org/gynecologic-cancer-guidelines.\nPatient information is available at www.cancer.net.\nRELATED ASCO GUIDELINES\n• Germline and Somatic Tumor Testing in Epi-\nthelial\nOvarian\nCancer:\nASCO\nGuideline30\n(https://ascopubs.org/doi/full/10.1200/\nJCO.19.02960)\n• Patient-Clinician Communication: American Society", "section": "PARPi", "page_from": 24, "page_to": 24, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "1134fac5a4785e13844fa57900470632b52b4c52626d55841ffa275438159a83"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000112", "text": "• Germline and Somatic Tumor Testing in Epi-\nthelial\nOvarian\nCancer:\nASCO\nGuideline30\n(https://ascopubs.org/doi/full/10.1200/\nJCO.19.02960)\n• Patient-Clinician Communication: American Society\nof Clinical Oncology Consensus Guideline36 (http://\nascopubs.org/doi/10.1200/JCO.2017.75.2311)\nAFFILIATIONS\n1Memorial Sloan Kettering Cancer Center, New York, NY\n2American Society of Clinical Oncology, Alexandria, VA\n3SHARE Cancer Support, New York, NY\n4Ovarian Cancer Research Alliance, New York, NY\n5Ovarian Cancer Project, Williamsville, NY\n6The Royal Marsden NHS Foundation Trust and Institute of Cancer\nResearch, London, United Kingdom\n7Kaiser Permanente, San Francisco, CA\n8DeCesaris Cancer Institute, Anne Arundel Medical Center, Annapolis,\nMD\n9National Cancer Institute, Bethesda, MD\n10University Health Network, Toronto, Ontario, Canada\n11Dana-Farber Cancer Institute, Boston, MA\n12Stephenson Cancer Center, Oklahoma City, OK\n13University of New Mexico, Albuquerque, NM\n14Virginia Cancer Specialists, Arlington, VA\n15Cedars-Sinai, West Hollywood, CA\n16University of Texas MD Anderson Cancer Center, Houston, TX\nJournal of Clinical Oncology\n3491\nPARP Inhibitors in Ovarian Cancer", "section": "PARPi", "page_from": 24, "page_to": 24, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "bf59ce2a4d745bc87863f71fecd623c577e410cc9e70886a150e7099c5570d29"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000113", "text": "15Cedars-Sinai, West Hollywood, CA\n16University of Texas MD Anderson Cancer Center, Houston, TX\nJournal of Clinical Oncology\n3491\nPARP Inhibitors in Ovarian Cancer\nDownloaded from ascopubs.org by 23.247.137.158 on October 24, 2025 from 023.247.137.158\nCopyright © 2025 American Society of Clinical Oncology. All rights reserved.", "section": "PARPi", "page_from": 24, "page_to": 24, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "3c134ea267a26c09d3fbd397b56e9732a80249272d779e7fb0af765ab0ec91e2"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000114", "text": "CORRESPONDING AUTHOR\nAmerican Society of Clinical Oncology, 2318 Mill Rd, Suite 800,\nAlexandria, VA 22314; e-mail: guidelines@asco.org.\nEQUAL CONTRIBUTION\nW.P.T. and E.C.K. were Expert Panel co-chairs.\nEDITOR’S NOTE\nThis American Society of Clinical Oncology (ASCO) Clinical Practice\nGuideline provides recommendations, with comprehensive review and\nanalyses of the relevant literature for each recommendation. Additional\ninformation, including a supplement with additional evidence tables,\nslide sets, clinical tools and resources, and links to patient information at\nwww.cancer.net, is available at www.asco.org/gynecologic-cancer-\nguidelines.\nAUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF\nINTEREST AND DATA AVAILABILITY STATEMENT\nDisclosures provided by the authors and data availability statement (if\napplicable) are available with this article at DOI https://doi.org/10.1200/\nJCO.20.01924.\nAUTHOR CONTRIBUTIONS\nConception and design: All authors\nCollection and assembly of data: William P. Tew, Christina Lacchetti, Elise\nC. Kohn\nData analysis and interpretation: All authors\nManuscript writing: All authors\nFinal approval of manuscript: All authors", "section": "CORRESPONDING AUTHOR", "page_from": 25, "page_to": 25, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "560d2d70dc7634f33f374326581f0a583d2632bac6b6add31d1f26c8dad6c07a"}
{"doc_id": "acco_parpi__v00000000", "chunk_id": "000115", "text": "C. Kohn\nData analysis and interpretation: All authors\nManuscript writing: All authors\nFinal approval of manuscript: All authors\nAccountable for all aspects of the work: All authors\nACKNOWLEDGMENT\nThe Expert Panel wishes to thank Rachel Grisham, MD; Christopher Lao,\nMD; Tracey Weisberg, MD; Corrine Zarwan, MD; Jonathan Ledermann,\nMD; and the Clinical Practice Guidelines Committee for their thoughtful\nreviews and insightful comments on this guideline.\nAPPENDICES\nAll Appendices and Acknowledgment material (including the table of\nExpert Panel members) are online only. It will appear on JCO website\nonline but not in the print version.", "section": "CORRESPONDING AUTHOR", "page_from": 25, "page_to": 25, "display_name": "acco_parpi", "version": "v00000000", "created_at": "2025-11-28T06:04:58", "hash": "ea141d079cb1ba323a045d626106a33bcb1a085f35cddd6e320de56125e1c77a"}
